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ABSTRACT
This work is the result of an investigation into aspects of
prolactin and dopamine in primary affective disorders. It
is introduced by a discussion on the need for obtaining
good scientific data on the organic and psychosocial aspects
of psychiatric illness, and in particular, primary affective
disorders. A short perspective of the history of depressive
illness preceeds the review of relevant scientific literature
on primary affective disorder. The literature survey covers
aspects which indicate organic causal factors as well as
viewing numerous organic studies which are thought to be rele-
vant to this investigation. The role of dopamine in motor
behaviour is considered in some detail. Psychopharmacological
evidence that the mesolimbic and nigrostriatal dopaminergic
systems are involved in motor regulation is reviewed. The
role of dopamine receptors in motor behaviour is important to




receptors are considered and the opposing roles of these re-
ceptors is thought to be significant. Drugs affecting manic
and depressive phases of primary affective disorders are re-
viewed. Emphasis is placed on dopaminergic aspects of various
drugs in primary affective disorders as with pimozide as an
antimanic agent, and nomifensine as an antidepressant. The
possible role of noradrenaline in learning and mood regula-
tion and in the dialogue with dopamine is looked at from an
experimental and clinical point of view.
Dopaminergic control of prolactin is reviewed and in part-
icular the nature of the D
4 
receptor. The fact that these
receptors which are on the pituitary mammotrophs have simil-
arities to the D
2 
receptors is relevant. Thus considerable
commonality exists between the dopaminergic regulation of
motor behaviour and regulation of prolactin. Prolactin is
used as an index of dopamine function in patients with pri-
mary affective disorders. Motor behaviour is strongly in-
fluenced by affective disorders.
iv
The central theme of the study itself was to indirectly eval-
uate dopamine function in primary affective disorder by
measuring prolactin levels. As strong tonic inhibition is
exerted by dopamine on prolactin, a series of challenges to
the dopamine system was decided upon in order to generate a
number of serum prolactin values. A dopamine agonist L-di-
hydroxyphenylalanine (indirect) and an antagonist, chlorpro-
mazine, were used to stress the system mildly.
The procedure was carried out under standard conditions both
in the illness phase and upon significant recovery. Both
these investigations were conducted in a drug-free state.
The data generated was subjected to statistical analysis.
The results of the analysis suggests that prolactin levels
are low in depressed patients, and increase upon recovery,
while manic patients have elevated levels which decrease
with recovery.
The pattern of the curves obtained from the challenge pro-
cedure suggests a possible supersensitivity of dopamine
receptors in the manic patients. Blunting of responses of
depressed patients remains a possibility but a study against
normal controls is required to further assess this aspect.
Evidence is therefore found for altered prolactin levels in
illness phases of primary affective disorders. This is
thought to be due to an abnormality in the dopamine regula-
tion of prolactin.
A discussion on the possible mechanisms and significance of
these changes involves Beta-endorphin in an attempt to tie
motor changes to mood regulation.
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Comprehensive understanding of both normal and disturbed
behaviour requires that we have a good knowledge of the
neurobiophysiology, the psychology and the social and enviro-
mental influences on behaviour. It is only in recent times
that good progress is being made in the understanding of the
organic aspects of behaviour. The development of new techni-
ques of measurement and data collection has made this pos-
sible. Psychiatrists who wish to work in this field need to
extend their training in the neurosciences. Better insight
into the physiology of behaviour should be complementary to
the psychosocial aspects of human function, rather than
oppositional. This study is in pursuit of a greater under-
standing of the organic aspects of abnormal behaviour, part-
icularly in a situation where there is evidence for a strong
pathophysiological contribution.
The understanding of what appear to be pathological states
have a real possibility of improving our concepts of normal
physiology. The caricature which certain conditions produce
may heighten the probability of seeing the physiological com-
ponents and thereby not not only contributing to the under-
standing of the pathology, but also to the normal physiology.
The emphasis is on the physiology of the individual, but
this is no denial of the importance of the psychological in-
fluences, social milieu and other environmental factors.
More data on all these components is absolutely essential to
a better understanding of behaviour and its aberrations.
This study concentrates on the former aspect.
The choice of subjects was influenced by the data which in-
dicates that primary affective disorders are relatively
discrete, in particular the bipolar form. Fairly good cri-
teria exist for diagnosis. Genetic factors are apparently
strong. Response to physical treatment is superior to any
2
other treatment in the field of psychiatry. This suggests a
potent physiological contribution. In view of the above
factors and of many investigations which suggest disturbed
neurophysiology, this group of patients seem to be good sub-
jects for physiological study. They are relatively homo-
geneous.
Factors which further influenced the study, and the methadol-
ogy used, were the periodic nature of the condition, indeed
its therapeutic reversabilitv, and the possibility of seeing
the same patient in two different clinical states. These
two contrasting states, mania and depression, are both mani-
festations of the same disease. It was therefore possible
to see the subjects in one and/or other illness phase and in
a recovery phase. The subjects could then act as their own
controls. This strategy has difficulties attendant upon it.
Of particular interest is the matter of whether the chemical
indices used would measure a trait factor rather than a
state factor, in which case it could be difficult to see the
pathological aspect, in view of normal controls not being
used. Fortunately this did not prove to be a problem, in
fact the strategy probably enhanced the incisiveness of the
study as shifts could be seen for values lying for the most
oart within normal limits.
In the review of literature it can be seen that biogenic
amines have been the subject of extensive study in primary
affective disorders. It would be naive to think that such
multifaceted behaviour disturbance is the result of a single
biogenic amine pathology. The probability of complex neuro-
physiological changes being responsible for this condition
is high. Noradrenergic functional pathology in primary aff-
ective disorder has many proponents, as indeed has serotonin.
Both dopamine and acetylcholine have been rather neglected
by researchers in this area. In view of the strong changes
in motor behaviour attendant upon attacks of primary affec-
tive disorder, it was decided to investigate dopamine.
From the review of literature it can be seen that fairly
3
compelling evidence exists for the involvement of dopamine
in the regulation of motor behaviour. The view is that
dopamine may contribute significantly to the motor compon-
ent of a complex neurophysiological disturbance, possibly
involving noradrenaline, acetylcholine and peptides amongst
others.
Investigating dopamine is a difficult problem and is limited
by the available technical facilities allowing only indirect
measurements in vivo at present. A dopamine system readily
available to indirect assessment is the prolactin regulating
system. A set of challenges with dopamine enhancing and dop-
amine blocking substances was considered desirable in order
to stress the system mildly. A number of values for prolac-
tin both in an illness phase and in a recovery period were
obtained. It was naively hypothesized that the depressed
state would be associated with a hypodopaminergic condition
and might therefore be reflected in elevated prolactin lev-
els. On the other hand mania would be the inverse and pro-
lactin levels could be expected to be low. The hypothesis
was based in part on the tonic dopaminergic inhibitory con-
trol of prolactin secretion. This proved to be an over-
simplification and indeed the entire hypothesis was inverted
following the results obtained. Having looked at the dopa-
mine regulation of prolactin in primary affective disorders
the question is, can the findings be extrapolated to other
central dopamine systems? When considering other evidence
in relation to dopamine in primary affective disorders it
seems possible that this may not be a purely local dopamine/
prolactin aberration. Dopamine functions in other systems
may also be altered in this group of patients.
It is hoped that this study may contribute a small amount of
data to the larger pool. In time accumulation of data may
allow a more cohesive and comprehensive understanding of the
pathophvsiologv of primary affective disorders and possibly





....for sorwful ymagynacion is always hoolly in my mynde....
this melancholy and drede I have for dye, defaute of slepe
and hevynesse bath sleyn my spirit of quycknesse that I have
lost al lustihede (happiness)....I have suffered this eight
yere and yet my boote (cure) is never the nere: for ther is
phisicien but oon that may me hele...."
Chaucer 1372
2.1 ORIGINS
The history of madness is inextricably enmeshed with theology,
demonology, witchcraft and folklore. Civilised societies of
today still retain fragments of these beliefs while preliter-
ate and transitional cultures, as can be seen in Africa, are
steeped in mystical beliefs about madness. The cause of mad-
ness in these cultures may be related to the ancestors (amad-
lozi) having been angered. It is interesting to note that
the European cultures have frequent references to states of
lowered mood, and much literature has specific terms refer-
ring to depression (outlined later). There does not appear
to be clarity of terminology in many of the African cultures
where symptoms of depression are referred to rather than a
more specific "nosological" term, for instance, "my blood
is cold" (igazi liya banda). European literature and folk-
lore is replete with reference to melancholia, which is a
very well developed concept.
2.2 GREEK CONCEPTS
Supernatural powers played a very important part in madness
in early Greek culture. Evil spirits which emanated from
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"dread goddesses" such as goddess mania, could be sent by the
angered gods. The "cult of the dead" is frequently seen in
preliterate cultures (as in Africa) and was present in early
Greek culture. The Greeks had cultural "treatment" rituals
which were to appease the angered gods. Many African tribes
also have clear cultural treatment rituals which are perfor-
med to pacify their displeased ancestors.
There was little attention paid to the legal status of the
afflicted persons.
The physicians concerned with the medical treatment of psychi-
atric patients developed some fairly systematized ideas on
treatment and mental illness. Hippocrates (Friedman and Kap-
lan,1967) in the 4th century B.C. wrote on the four humours -
blood, black bile, yellow bile and phlegm. The temperament
of a person was related to the dominance of a humour. The
English derivates from these concepts are still with us to-
day - sanguine, melancholic, choleric and phlegmatic! Since
the 5th century B.C. the notion that the brain had an impor-
tant function with the senses and intellect resulted in Hip-
pocrates writing "...and by the same organ (the brain) we
become mad and delirious, and fears and terrors assail us".
He also said that "joys and delights" and "sorrows and grief
and despondency" originated in the brain.
"Melaina chole" (black bile) is the origin of melancholia
which is still in use today. Melancholia unmistakably re-
fers to depressive conditions (affective disorders), which
were thought to be caused by an excess of black bile. Treat-
ment at that time was very poor, unless purgation could be
considered a type of counter irritation! Bathing and diets
were also frequently prescribed.
2.3 ROMAN INFLUENCES
The Romans were influenced by the Greek concepts and the
great physician Galen (Friedman and Kaplan, 1967) was
particularly taken by the theory of the humours. Galen
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devoted a considerable amount of time to melancholia, re-
cognising the central position of despondency (dysthymia)
and fear (anxiety). Description of sub-types flowed from
his pen. Galen's concepts of health and disease were almost
the "anlage" of our present theories of melancholia. The
right balance of the humours (transmitters) were necessary
for health. An excess of black bile "melaina chole" (per-
haps acetylcholine) would give rise to a dreadful despond-
ency (melancholia). It is only very recent research that
is looking closely at an excess of cholinergic activity as
being a factor in depression. This analogy may, of course,
be entirely fortuitous - is it not closer to the truth than
Freud's views on depressive illness? Galen believed that
the treatment of melancholia was corrective education
(psychotherapy).
At least two writers of the 1st century B.C. described mania.
Asclepaedes recognised a state of excitement which was not
associated with fever. It was continuous and unabating for
considerable periods.
Aretaeus anticipated the great Kraepelin in describing mel-
ancholia which terminated in a state of excitement (mania).
Here was an incipient concept of a unitary condition which
could give rise to depression and excitement (manic depres-
sive disorder).
Treatment by certain physicians had become more enlightened.
Modification of the environment and the development of a
relationship(s) could be prescribed.
2.4 MIDDLE AGES
The Middle Ages were not associated with remarkable develop-
ments in the field of affective disorders. Alexander of
Tralles described a disorder of a circular type, which had
alternating periods of melancholia and mania.
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The entwinement of psychiatric disorders with religious at-
titudes and witchcraft do not allow for clear recognition
of psychiatric conditions. Even the more rational and less
superstitious physicians could hardly escape the idea that
the devil must be lurking somewhere in the background. While
Christian influences at this time were not always favourable,
the Moslem influence in Arabia led to a much more humanit-
arian approach to the mentally ill. The Moslem belief that
the insane may be closer to God, or favoured by him, was
responsible for this sobering effect.
2.5 LITERARY CONTRIBUTION
European literature during this period dealt with the con-
dition of man. The presenting quotation of this work is
derived from Chaucer "....for sorwful ymagynacion is always
hoolly in my mynde....this melancholye and drede I have for
dye, defaute of slepe and hevynesse hath sleyn my spirit of
quycknesse that I have lost al lustihede (happiness)....I
have suffered this eight yere and yet my boote (cure) is
never the nere: for ther is phisicien but oon that may me
hele...."
It can be assumed that such a remarkable description of the
phenomenology of a depressive episode could only have been
the product of a sufferer from the condition!
William Shakespeare wrote profusely on the plight of people
in a literary manner of their "psychiatric" status. Hamlet
appears to have had considerable mood disturbance as ref-
lected in his quotation:-
"0, that this too, too solid flesh would melt, thaw and re-
solve itself into dew! Or that the everlasting had not
fix'd his canon 'gainst self-slaughter! 0 God! How weary,
stale, flat and unprofitable seem to me all the uses of
this world. Fie on't. 0, fie! 'Tis an weeded garden that
grows to seed; things rank and gross in nature possess it
merely."
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In his discussion on melancholy Burton (1932) made the fol-
lowing remarks:-
"In disposition, is that transitory melancholy which goes
and comes upon every small occasion of sorrow, need, sick-
ness, trouble, fear, grief, passion and perturbation of the
mind, any manner of care, discontent, and vexation of spirit,
any ways opposite to pleasure, mirth, joy, delight, causing
forwardness in us, or a dislike!"
Burton (1932) also discusses the species or kinds of melan-
choly and quotes Hippocrates as agreeing basically on three
types of melancholy; the first being from the brain - head
melancholy; the second from the whole body; and the third
from the bowels, liver, spleen or membrane called the mes-
enterium. The latter type is a hypochondriacal depression.
Whether the difference between the first and second is a
reactive/endogenous distinction is not clear. Certainly the
second type seems to be somatized or vitalised depression.
Burton quotes a number of authors who support the theory
that old age increases the risk of depression. He believed
it to run in families. "it being an hereditary disease".
He covers a wide variety of "etiological factors", from bad
diet and bad air to excessive exercise, enforced solitariness
and bad marriages.
2.6 THE ORIGINS OF SCIENTIFIC PSYCHIATRY
The 19th century German organic school of psychiatry which,
in my view, has contributed so much, was influenced by
Thomas Aquinas (Friedman and Kaplan, 1967) who entrenched
the organic and somatic approach. He rejected the concept
of the soul being involved in "psychiatric" disorder, and
laid the foundation for organic psychiatry. Melancholia and
pathological anger (possibly mania) were decribed by Thomas
Aquinas.
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Another important development was to follow Sydenham (Fried-
man and Kaplan, 1967), whose descriptive approach produced
the thrust for 17th and 18th century descriptive psychiatry.
An interesting discussion on mania by William Cullen in the
18th century focuses on two interesting aspects; firstly, he
considered that mania was the result of a disorder affecting
the brain, and that some "energy imbalance" in the nervous
system could be involved in its causation and secondly, the
treatment recommended was sedation with opium.
Here is evidence of an early attempt at rational psychophar-
macological intervention. While this was not the first
pharmacological thera2y it had rational grounds. It is
known that the use of extracts of Rauwolfia Serpentina had
been used in preliterate times in India, to control behav-
iourally disordered people. The subsequent identification
of reserpine as the active ingredient has contributed to our
understanding of brain function (Bowman and Rand, 1980).
2.7 THE ORGANIC SCHOOL
It was against this 17th and 18th century development that
Kraepelin (1921) made his contribution. He was extensively
schooled in the "organics" of the nervous system, while be-
ing somewhat limited in his social view of behaviour. This
heavily organic, and patient orientated view, combined with
the extensive collection of relevant data, culminated in a
major step in psychiatry; the clear unification of melan-
cholia and mania into the manic depressive psychosis and its
separation from schizophrenia (dementia praecox).
While Kraepelin's contribution may not have been appreciated
by American psychiatry, which to its folly followed a con-
temporary of Kraepelin's (Sigmund Freud), Europeans contin-
ued their interests in organic psychiatry. Investigation
into body form and temperaments/psychiatric illness was led
by Kretschmer (Slater and Roth, 1969). His prototypes are
well known and of relevance, the pyknic type was thought to
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be extroverted, cyclothymic and even manic depressive. Shel-
don (Slater and Roth, 1969) did a similar study, but his
terminology was somewhat different.
2.8 AFFECTIVE DISORDERS
The term "affective disorders" has become an accepted term
incorporating many conditions where depression (and, by
some authors, - anxiety) is part of the central theme. Its
usefulness is in allowing a large number of both minor and
major conditions with significant mood change to be consid-
ered together. The biological sub-group of the affective
disorders is usually referred to as the primary affective
disorder being the group which is now under consideration.
The Kraepelinian view that all major depressive conditions
could be subsumed under the heading of "manic depressive
psychoses", has been considerably refined in the last three
decades.
2.8.1 Bipolar and Uni'oolar 
There is now some compelling evidence that at least two sub-
groups of primary affective disorder exist, the bipolar and
unipolar. The distinction is supported by evidence from
Perris (1969), Gershon et al, (1979).
These are but a few of the genetic studies referred to later.
Other approaches to this problem have been the investigation
of biochemistry, treatment response, and the course of the
condition. At present there is considerable theoretical
support and practical usefulness in the bipolar/unipolar dis-
tinction.
Attempts at further sub-division into bipolar I and bipolar
II (Dunner et al, 1976) seem to be both premature and not
very useful. The relationship of affective disorders to
schizophrenia remains a difficult one.
1 1
2.8.2. Schizo-affective 
Kasanin (1933) introduced the term schizo-affective in at-
tempting to deal with the interface between schizophrenia
and manic depressive illness. Leonhard was also involved
in this difficult area in his studies of atypical psychoses.
These are matters that need further clarification. Although
Pope and Lapinsky (1978) have drawn attention (rightly so,
especially in the U.S.A.) to the probable misdiagnosis of
manic depressives as schizophrenics, they have not materi-
ally contributed to the understanding of the relationship
between schizophrenia and bipolar primary affective disorder.
2.8.3. Reactive/Neurotic - Endogenous Distinction
The relationship between reactive depression and pathologi-
cal (endogenous) depression remains another difficult area;
while at the extremes of the clinical picture of endogenous
and reactive depression the distinction is clearly valid and
useful, there is an enormous blur between these two poles.
Aubrey Lewis (1938) argues that depressive illness is a con-
tinuum from mild to severe. Kendall (1976) has supported
this view that the spectrum is from mild/chronic to acute
psychotic depressive states.
Whatever the theoretical truth may be, the practical issue
is clear. Those patients with endogenous symptomatology
will respond better to physical and pharmacological treat-
ment with antidepressant agents.
2.8.4. Convulsive Therapy 
The introduction by Meduna (1935) of convulsive therapy has
been a major stride in psychiatric treatment which has since
been modified by the introduction of electrical induction
(Ugo Cerletti 1938); the use of anaesthesia and skeletal
muscle relaxants; and the refinement of equipment and in-
dications. Convulsive treatment of primary affective
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disorders remains the most effective intervention for the
present attack, and may often be life saving (Kendall 1981).
2.8.5 Pharmacological Advances 
The last three decades have seen unprecedented development
in the field of psychopharmacology.
The introduction of imipramine and chlorpromazine in the mid-
nineteen fifties saw the beginning of a revolution in the
treatment of severe psychiatric disorders.
Affective disorders have benefited from an expansion of
available antidepressants, the second generation drugs having
good efficacy with less side effects. The management of
mania has become far more effective with the use of neuro-
leptics such as chlorpromazine and haloperidol, and the use
of lithium carbonate (Cade 1949). Lithium has undoubtedly
been a major advance as it is most useful as a prophylactic
agent.
The recognition that monoamine oxidase inhibitors have the
capacity to reverse depressive states, emerged from the
early treatment of tuberculosis. These drugs remain a use-
ful part of the armamentarium of managing primary affective
disorders.
Modern pharmacology has had a profound effect on behavioural
science. The understanding of drug action and its ability
to penetrate brain and behaviour, should come as no surpise.
As a result of a wide variety of experimental and therapeu-
tic psychopharmacological and biochemical techniques, we
stand at the brink of a new understanding of behaviour. It
is hoped that this work might contribute a small amount to
this body of evidence.
2.8.7 Social Data
Finally the era of social data has broken upon us with brown
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(1978), and others, collecting objective data on the influ-
ence of environment, such as the family and life events on
the course of depressive illness.
No review has been made of the psychotherapeutic aspects of
primary affective disorders, as it is with the organic as-
pects of primary affective disorders that this investigation
is concerned. It is considered that psychotherapy is out-




3.1 GENETICS AND PRIMARY AFFECTIVE DISORDERS
Genetic factors play a vital role in the production of a vul-
nerability to primary affective disorders. This fact in-
creases the probability that investigation of nervous system
function will find some biochemical deviation in this ill-
ness.
The evidence that genetic factors play an important role in
primary affective disorders is unequivocal today, and is ac-
cepted by all experts working in this field. The problems
that remain relate to the mode of inheritance, and to the
homogeneity of the primary affective disorders.
Most of the genetic work has relied on twins studies as well
as adoptive and family studies. No attempt will be made to
review all the literature, only a short summary of the im-
portant findings will be given.
Pooled data from seven twin studies in affective disorders
give overall concordance rates of 76% in monozygotic twins,
contrasting with concordance rates of 19% in dizygotic twins,
(Rosanoff et al, 1935, Kallman 1942, Slater and Roth, 1969,
Tsuang, M.T. 1975).
The concordance rates are not materially altered by the rear-
ing apart of monozygotic twins! This is a profound finding
(Price 1968).
Genetic linkage studies are still advancing. Claims by Wino-
kur of X-linkage (using X-ga blood group and colour blind-
ness as markers) have complicated the picture as to the mode
of inheritiance. Winokur found a striking lack of ill-father/
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ill-son pairs in the families he studied (Winokur and Tana
1969). Other studies have not, however, supported this view
fully and reports of ill-father/ill-son are well documented
(Perris 1973).
Evidence suggestive of some cases of X-linkage, or X-associ-
ation, does exist. There may, however, be more than one gene
involved in the inheritance of this condition.
Angst (1966) and Slater (1969), and others, suggest a single-
autosomal dominant gene of reduced penetrance as the most
likely mode of inheritance.
The question of heterogeneity has been under investigation.
There is some evidence that at least two sub-types of primary
affective disorders exist - (a) the bipolar type, and (b) the
unipolar type. These two types appear to breed true with in-
significant risk of unipolars arising from bipolar stock, or
bipolars arising from unipolar stock (Perris 1966).
On a broad front no documented cases exist where one member of
a monozygotic twin pair has a different psychosis from the
other, excluding those single twin members who may have suf-
fered an event, for instance, brain damage. Cohen (1972)
conducted a study of 260 pairs of twins who had presented with
manic depressive illness (40), schizophrenia (194) and schizo-
affective disorders (26). No single case was reported where
the type of psychoses - differed in a monozygotic twin pair.
The risk of primary affective disorders in the general popu-
lation is about 1%. The risk to a first degree relative is
about ten-fold this figure (Zerbin-RUbin 1961).
There is abundant evidence for powerful genetic factors pro-
ducing vulnerability to primary affective disorders. The
challenge that flows from this information is, how does the
genetic factor influence the chemistry and physiology and,
what is the interaction between organic vulnerability and
environmental influences?
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3.2 RELEVANT PHYSIOLOGICAL AND PHARMACOLOGICAL FACTORS
The organic aspects in primary affective disorders relevant
to this study will be reviewed from the literature. The
short overview of genetics merely underscores the importance
of these organic components. The review will include a wide
variety of approaches, which may have bearing on the functions
under investigation. Work on intracranial self-stimulation
is included as it is involved with the catecholamine systems
and is heavily influenced by psychoactive drugs used in pri-
mary affective disorders.
3.3 DOPAMINERGIC SYSTEMS OF THE BRAIN
3.3.1 The Mesotelencephalic Dopaminergic System
3.3.1.1 The Mesolimbic System
The dopaminergic cells of the mesolimbic system lie in thc
ventral tegmental area A.10 (Fig. 1 & 2). A small amount of
innervation also arises from the cells in area A.9 (van Roo-
yen 1980). These neurones terminate on a number of limbic
structures:-
a) the nucleus accumbens septi;
b) the amygdala and septum;
c) the olfactory tubercle;
d) The interstitial nucleus of the stria terminalis.
3.3.1.2 The Mesocortical System
The neurones of the mesocortical system reside in area A.9
and A.10 (Fig. 1 & 2) and are distributed to the frontal cor-
tex and the cingulate gyrus. Projections also occur to the
suprarhinal and ventral entorhinal cortex and antero-medial





























































3.3.1.3 The Nigrostriatal Dopaminergic System
The cell bodies in this system lie in the substantia nigra,
area A.8 and A.9 and terminate in the neostriatum Fig. 1 &
2) (DahlstrOm and Fuxe, 1964).
3.3.2 Hypothalmic Dopaminergic Systems 
3.3.2.1 The Tuberohypophyseal Systems 
This system projects to the median eminence, neural lobe and
pars intermedia of the hypophysis (Fig. 1 & 2). The cell
bodies lie in the arcuate A.12 and periventricular nucleii.
Many of the terminals in the median eminence are packed
against the portal system. The system releases dopamine in-
to the portal vessels carrying it to the anterior pituitary
(Bjorklund et al, 1970).
This is not a complete review of the dopaminergic systems,
but is restricted to those systems which are thought to be
relevant to motor function and motivation. The tuberohypoph-
vseal system is included, as it constitutes the experimental
system, which may reflect possible changes in the motor dopa-
minergic systems.
3.3.3 Other Dopaminergic Systems 
a) the incertohypothalmic system;
b) the periventricular system;
c) the periglomerular dopaminergic neurones;
d) the retinal system;
e) the chemo-emetic trigger system.
3.4 DOPAMINE RECEPTORS
3.4.1 Non-Adenylate Cyclase Associated Dopamine Receptors 
And Receptors Negatively Regulating Adenylate Cyclase
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3.4.1.1 Dopamine 2 Receptors (D 2 )
The D
2 
receptors are non-adenylate cyclase dependent recep-
tors (Kebabian and Calne, 1979). Physiological concentra-
tions of dopamine at the micromolar level exerts influence
on these receptors. Therapeutic levels of antipsychotic
agents at nanomolar levels block these receptors.
The distribution of the D
2 
receptors is in the following
dopamine systems:-
a) the nigrostriatal system;
b) the mesolimbic system;






d) the chemo-emetic trigger zone.
Increased numbers of D
2 
receptors have been reported in
schizophrenics at post mortem, particularly in the limbic
area. This is reported in both treated and untreated pat-
ients. Studies show that micromolar concentration of dopa-
mine and nanomolar concentrations of antipsychotic agents,
are liable to displace radioligands from these receptors.
The evidence is reasonably clear that this is the receptor
site of action of the antipsychotic agents (Walters 1983).
3.4.1.2 Dopamine Receptors on Pituitary Mammotrophs (D 4 )
According to Kebabian (1978) the mammotrophs in the adeno-
hypophysis have D 2 like receptors which do not regulate
adenylate cyclase. The receptors appear to be extremely
sensitive, responding to concentrations of dopamine in the
namomolar range (2 - 4 nanomolar). These are the concentra-
tions of dopamine which are physiologically concerned with





H-ergot are used as ligands for these receptors (Wal-
ters 1983). The concentrations of antipsychotic agents to
21
which these receptors respond are nanomolar, that is, thera-
peutic levels. More recently a number of workers have re-
ported D 2 receptors negatively regulating adenylate cyclase.
Giannattasio and co-workers (1981) reported dopamine recept-
ors in the anterior pituitary of female rats which inhibited
adenylate cyclase. They believe that these receptors show
pharmacological similarities to the prolactin inhibiting re-
ceptors.
Apparently the female rat anterior pituitary contains the rel-
evant cells in far greater numbers than the male rat pituit-
ary, which failed to demonstrate significant adenylate cyclase
inhibition.
These researchers have also Produced evidence that this inhib-
ory effect of dopamine on adenylate cyclase is entirely depen-
dent on guanosine-5-triphosphate. Cote and co-workers (1982)
support the dependence of adenylate cyclase inhibition on
guanosine-5-triphosphate. Their study was conducted on the in-
termediate lobe of pituitary in relation to the synthesis and
secretion of alpha-melanocyte stimulating hormone. It there-
fore appears that dopamine receptors of D 2 type exist in the
anterior and intermediate lobes of the pituitary. The inhib-
ition of adenylate cyclase by these receptors is dependent
on guanosine-5-triphosphate. In the anterior pituitary they
probably play a part in the inhibition of prolactin secretion.
Stoof and Kebabian (1981) demonstrated D
2 
dopamine receptors
in the neostriatum of the rat which are negatively linked to





receptors in the neostriatum with opposing roles
mediated by their contrasting effects on adenylate cyclase.
3.4.1.3 Dopamine 3 Receptors - Autoreceptors (D 3 )
Another group of receptors, D 3 , which do not regulate adeny-
late cyclase are the autoreceptors. A significant proportion
of these receptors are presynaptic in their location, for in-




control of negative feedback loop on dopamine synthesis and
release. These receptors are sensitive to nanomolar con-
centration of dopamine, which is considerably lower than the




 are sensitive. It is pos-
sible to obtain selective agonistic activity by apomorphine
at the D
3 
receptor site (pre-synaptic non-adenylate cyclase
dependent system). The concentration of most antipsychotic
agents to which D 3 receptors are sensitive are in the micro-
molar range. When low concentrations (nanomolar) of apo-
morphine are used the behavioural effect is one of lethargy
and sedation, due to the differential effect on D
3 
recep-
tors. When higher concentrations are used, the D 2 receptors
are involved, the animal shows increased locomotor activity
(Meltzer 1982) due to predominant effects on these post-
synaptic dopamine receptors.
3.4.2 Dopamine Receptors Positively Regulating Adenylate 
Cyclase (D 1 )
Dopamine and 2-amino-6, 7-dihydroxy-1,2,3,4,-tetrahydronaph-
thalone are full agonists on adenylate cyclase linked dopa-
mine receptors, while apomorphine is a partial agonist.
Micromolar range of agonists are required for the stimula-
tion of dopamine sensitive adenylate cyclase (EC5O's e.g.,
dopamine 2 x 10 -6 ' 2-amino-6,7,-dihydroxy-1,2,3,4,-tetrahy-
dronapthalone 4 x 1
-6 
and apomorphine 2 x 10
-6
). The value
as seen here for dopamine is at physiological levels (Keb-
abian et al, 1975).
The concentration of antagonists necessary to inhibit dopa-
mine sensitive adenylate cyclase is supra-therapeutic (IC50's
are around 6 x 10
-7
). The neuroleptics in plasma are in the
nanomolar range. These substances are, therefore, weak in-
hibitors of dopamine sensitive adenylate cyclase (Walters
1983).
3.5 DOPAMINE SYNTHESIS


































neurone and is transported to the nerve terminals where it
is stored in two forms - the protein bound granular form
(in vesicles) and a non-granular form (Blaschko 1953).
The storage system in vesicles consists of both stable and
labile components.
3.6 DOPAMINERGIC SYSTEMS AND BEHAVIOUR
Fundamental to the theoretical construct of this study is the
position of dopamine in relation to motor behaviour. Part
of the evidence will be reviewed here, the remainder is dealt
with in the appropriate sections.
Manipulation of dopaminergic function by various pharmaco-
logical agents and strategic combination of agents, together
with lesioning experiments has produced some enlightening
information.
The action of amphetamines, as dicusssed in more detail else-
where, is via dopamine and noradrenaline. Lew doses of amph-
etamines (lmg./kg. body weight) produces motor arousal, i.e.
exploratory running behaviour, which is well integrated
(Ungerstedt and Ljunberg, 1973).
High doses of amphetamines (5-10mg./kg.) produce high freq-
uency repetitive brief "snatches" of behaviour; at first
grooming repeatedly and later stereotyped sniffing at high
frequency.
Treatment with alpha-methyl-para-tyrosine is associated with
attenuation of these motor phenomena. The nigrostriatal
system is known to be damaged in Parkinson's disease, where
there is relative akinesia (lack of initiation of movement)
as well as rigidity and tremor. L-dihydroxyphenyialanine
imoroves these symptoms. Injection of 6-hydroxydopamine
into the substantia nigra bilaterally, produces a profound
loss of dopamine in this system. Where extreme loss of
dopamine occurs motor arrest is seen (lack of initiation of
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movement). High doses of amphetamine fail to produce stereo-
typed behaviour in these animals. The rapidly repeated
stereotyped behaviour is, therefore, thought to be related
to nigrostriatal hyperactivation where the new movement be-
gins before the preceding seauence is completed. Low doses
of amphetamine are, however, able to produce behavioural
arousal, exploratory running in these animals! This sug-
gests that motor arousal, or the driving of motor behaviour,
is from a different source and that the substantia nigra is
involved in the execution of motor behaviour. This is fur-
ther evidenced by the asymetrical effects on motor activity
of unilateral lesions of the substantia nigra. Stimulation
of motor activity under these circumstances produces rota-
tional asymetry; amphetamine causing rotation towards the
side of the lesion and apomorphine producing rotation away
from the lesion. The latter effect is due to dopamine re-
ceptor supersensitivity in the damaged system.
The mesolimbic system has been similarly studied. Lesions
of the nucleus accumbens septi produce distinctly different
effects from those of the substantia nigra. Low doses of
amphetamines fail to produce motor arousal following lesions
of the nucleus accumbens septi (Kelly et al, 1975). It is
possible, however, in this preparation to illicit stereotypy
on high doses of amphetamines, the nigrostriatal system be-
ing intact. The local injection of dopamine, amphetamine,
or apomorphine into the nucleus accumbens septi leads to a
relatively short lived, but distinct increase of locomotor
activity (Pijnenberg et al, 1976). This effect can be in-
cisively blocked by local injection of haloperidol (Cools
1977). Apomorphine is a full agonist at the D 2 receptors
and a partial agonist in the D
1 
receptors.
Bromocriptine is also a dopamine agonist and increases loco-
motor activity in animals (Corrodi et al, 1973) and it does
not stimulate adenylate cyclase (Fuxe 1978). This again
suggests that the receptor responsible for increased loco-




The increase of locomotor activity produced by apomorphine
in normal animals is not as well integrated as is the enhan-
ced locomotor activity produced by amphetamines (Ungerstedt
and Ljunberg,1973). The level of locomotor activity is
also greater with amphetamines. The addition of clonidine
to apomorphine increased the level of locomotor activity
(Maj et al, 1972) and its integration to approximately that
produced by amphetamines. The locomotor activity effects
of apomorphine are blocked by the local injection into the
nucleus accumbens septi or parenteral administration of
neuroleptics. The neuroleptics at normal therapeutic doses
appear to be acting on the D 2 receptors, rather than the D 1
receptors (Cools and van Rossum, 1976).
Rotational effects of unilateral nigrostriatal lesions are
modified by stimulation of the nucleus accumbens septi. It
is the rate of rotation that is increased by nucleus accum-
bens septi stimulation, but unilateral stimulation of the
nucleus accumbens septi does not affect the direction of
rotation. This is further evidence suggesting that the
nucleus accumbens septi instructs or drives behaviour and
may influence its rate, but not its pattern of execution
(Iversen 1977).
Bilateral injections of the D 1 receptor antagonists (ergo-
metrine) into the nucleus accumbens septi, leads to a more
sustained increase in locomotor activity after a latency of
about thirty minutes. This effect can be inhibited by the
local injection of dopamine.
The apparently reversed effect is probably due to the action
of these drugs on different receptors. Increased locomotor
activity may result, therefore, from dopamine agonists on
D
2 
receptors in the nucleus accumbens septi or by blocking
D
1 
receptors with ergometrine injected locally into the
nucleus accumbens septi (Cools 1977).
It appears that there may be a complex self-modulation of
dopamine, which effect is dependent on a different receptor
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from that which drives behaviour.
Mesolimbic structures support high rates of intracranial
self-stimulation as discussed later.
Enhancement of dopamine activity by direct, or indirect
agonists has been reported to induce "psychosis" and to
precipitate mania in patients (Goodwin et al, 1971, Post
1975, Parkes 1979). Substances used in the treatment of
primary affective disorders, the first and second genera-
tion antidepressants and monoamine oxidase inhibitors have
also been reported to promote mania. This information is
important in the management of primary affective disorders
because both antidepressants and/or the neuroleptics may
increase the "swinging" of bipolar patients.
Lesions of nucleus accumbens septi attenuate the increased
locomotor activity produced by drugs acting directly, or
indirectly, on the dopamine receptors. Evidence of the
interaction between noradrenaline and dopamine has also
been cited.
Ljunberg and Ungerstedt (1973) demonstrated that lesions of
the ventral noradrenergic bundle interfered with learning.
This role of noradrenaline in relation to dopamine has also
been investigated by Iversen and Frey (1980), amphetamines
enhancing learning and behavioural efficiency.
Lesions of the ventral tegmental area certainly regularly
disturb behaviour and interfere with learning and behaviour-
al efficiency. Forebrain release of dopamine seems to be
necessary for focusing and attending to environmental stim-
uli. Tassim et al, (1979) demonstrated that lesions of
noradrenergic ascending pathways reduced the levels of turn-
over of dopamine in the ventral tegmental and cortic.D.-,'
limbic areas.
Noradrenaline has long been implicated in stress and the dia-
logue between noradrenaline and dopamine is probably involved
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in adaptive behaviour. It would indeed be surprising if
this was not so.
Noradrenaline appears to be important in learning effects,
bilateral lesions of the locus coeruleus is not associated
with reduced rates of running in a maze, but with impaired
learning. These noradrenergic systems seem to be respon-
sible for the "reinforcing" effects on behaviour. This re-
inforcement is presumably contingent upon bio-socially suc-
cessful behaviour.
3.7 NORADRENERGIC SYSTEM IN BEHAVIOUR
3.7.1 The Anatomy of Noradrenergic Systems 
3.7.1.1 The Ventral Noradrenergic System
The cell bodies of the ventral noradrenergic system lie in a
number of cell groups in the pons and medulla. The ventral
noradrenergic system runs to the hypothalamus (Fig. 4 & 5).
3.7.1.2 The Dorsal Noradrenergic System
The cell bodies of the dorsal noradrenergic system are loca-
ted in the locus coeruleus and the fibres run into the Pur-
kinjie cells of the cerebellum (inhibitory), and to the
frontal cerebral cortex and the pyramidal cells of the hip-
pocampus. Noradrenergic innovation of limbic and cortical
sites is, at least in part, concerned with aspects of associ-
ative learning (Kety 1970) (Fig. 4 & 5).
3.7.2 Function of the Noradrenergic Systems 
The release of noradrenaline is associated with reinforce-
ment and facilitation of learning and memory (Gray 1977).
Gray has produced evidence that for rats to be able to show
the partial reinforcement effect, the dorsal noradrenergic
bundle must be intact. I. this is correct, the noradrenergic

























of bio-socially successful behaviour, which is driven and
executed by dopaminergic systems. This makes noradrenaline a
very good candidate for mood regulation, in particular a
feeling of well-being (mood-elevation), as this is contin-
gent upon bio-social success and presumably reinforcement.
Further evidence of interaction between noradrenaline ascen-
ding pathways and dopamine in areas innervated by dopaminer-
gic cells from A.10 has been produced (Tassim et al, 1979).
Lesions of the ascending noradrenergic bundles resulted in
reduction of dopamine in the areas of distribution on dopa-
mine neurones from Area A.10. Noradrenaline exerted some
facilitatory influence on the dopamine neurones. Further
support for this is offered by the enhancing effect of clon-
idine on apomorphine in locomotor activity, again suggest-
ing an interaction of the noradrenergic systems on dopamin-
ergic systems.
It is, of course, possible that just such an interaction is
the basis of the experience of mood enhancement. Further,
locomotor activity produced by amphetamine is greater than
that produced by apomorphine alone. This suggest that
amphetamine, having effects on both dopamine and noradrena-
line displays an enhancing effect on dopaminergic function;
we also know that amphetamine enhances mood! Mason and
Iversen (1979) have, however, produced evidence, which at
least in part, contradicts this view and it seems that fur-
ther elucidation must be awaited (Mason and Iversen, 1979).
The problems associated with lesioning experiments are num-
erous. It is, therefore, vital that confirmation of all
work is obtained, preferably from more than one source.
3.7.3 Lesions of Transmitter Pathways 
Selective lesioning, e.g. by electrolytic technique or radio
lesions are not specific enough. 6-hydroxydopamine destroys
catechalamines containing neurones. Another problem is the
completeness of the lesion, for instance, one may get
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partial lesions. Other problems associated with lesions
are:-
a) increased turnover by surviving neurones;
b) higher electrical activity of the surviving neurones;
c) receptor responses may be increased.
Re-growth is also found in the catecholamine systems with
collateral growth (Raisman 1969, Masan and Koob, 1978).
Noradrenergic involvement in attention has also been mooted,
but requires further testing. This would certainly be con-
gruent with the ideas just considered.
3.8 PSYCHOTROPIC AGENTS, CATECHOLAMINES AND PRIMARY
AFFECTIVE DISORDERS
A review of psychoactive agents which affect primary affec-
tive disorders and catecholamines is of great interest and
relevance. Substances which alter the functional state of
the brain catecholamine systems and modify illness phases of
primary affective disorders throw light on the pathophysi-
ology of this condition. A number of substances are re-
viewed which are effective in altering the illness phase
of primary affective disorders. Other substances appear to
be active in modifying the functional state of the catechol-
amine systems whether normal or pathological. Correlations
between mechanisms of action and therapeutic and experi-
mental effects in normal and ill subjects are referred to.
These have yielded a wealth of circumstantial evidence about
the physiology of normal and abnormal behaviour.
This study is concerned with the possible role of dopamine
in affective disorders. The broader implication is also of
great interest, that is the role of dopamine in normal mo-
tor activity. A discussion of dopamine will inevitably in-
volve noradrenaline. The following sections deal in more
detail with these issues.
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3.8.1 Amphetamines and Related Drugs 
The mechanisms of action of amphetamines is primarily on the
catecholamines, acting indirectly on the dopaminergic and
noradrenergic systems (Quinton and Halliwell, 1963). In-
creased amounts of dopamine and noradrenaline are made av-
ailable at the receptor sites by releasing dopamine and nor-
adrenaline from the extra granular neuronal pools. This
effect can be attenuated by pre-treatment with alpha-methyl-
para-tyrosine a tyrosine hydroxylase inhibitor. Amphetamines
have also been shown to have a small amount of monoamine oxi-
dase inhibiting, and monoamine reuptake blocking effects.
Direct agonist activity has been mooted, but this seems to
be insignificant.
3.8.1.1 Effects on Man
The effects of amphetamines on human subjects is to increase
motor activity, to reduce appetite for food and to induce
euphoria. There is evidence that certain patients with bi-
polar affective disorder respond with more euphoria to amph-
etamines than do other depressives. The elevation of mood
may be an index of response to imipramine (Martin et al,
1971, Maas et al, 1972, Silberman et al, 1981).
There is suggestive evidence that amphetamines and appetite
suppressants (stimulants) are likely to induce mania in a
number of manic depressives (Gerner et al, 1976).
The chronic use of amphetamines (and other stimulants), par-
ticularly in increasing doses, is sometimes associated with
a psychotic state, usually of a paranoid type. It appears
that there is a difference in the effects of chronic abuse
as compared with acute use of amphetamines (Post 1975).
Amphetamines are associated with transient, and infrequent-
ly, with sustained improvement of mood in depressive patients.
The effects of amphetamines on locomotor activity in labora-
tory animals has been well documented. There is good
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evidence that they exert their motor effects via the dopa-
minegic system(s). Direct application of amphetamines to
certain dopaminergic systems will increase locomotor act-
ivity in animals. This is discussed in greater detail
elsewhere.
The selective antagonist, pimozide, reduced the locomotor
activity induced in animals by amphetamines. This sub-
stance is rather a specific dopamine antagonist, although
it has a fair amount of anticholinergic activity.
3.8.2 Drugs Affecting Primary Affective Disorders 
3.8.2.1 Tricyclic Antidepressants 
A wide variety of tricyclic antidepressants are available
and are efficacious in major depressive episodes of primary
affective disorders. The effects of the antidepressants
vary in the extent to which they act on noradrenaline, 5-
hydroxytryptamine and dopamine, as well as other neuro-
transmitters. There are those tricyclics which predominantly
affect catecholamines, in particular noradrenaline, and
are effective in reversing the depressive syndrome in a
significant proportion of patients (Daneman 1961). Desip-
ramine is of particular interest due to its predominant
action of noradrenaline reuptake, It is as efficacious as
imipramine (Mindham 1979).
3.8.2.2 Monoamine Oxidase Inhibitors and Second Generation 
Antidepressants 
The antidepressant actions of monoamine oxidase inhibitors
is probably due to the inhibition of the enzyme monoamine
oxidase. There is, therefore, a resultant increase in the
amount of dopamine and noradrenaline available, which enhan-
ces the dopaminergic functions.
Bipolar patients may respond better to monoamine oxidase
inhibitors than do unipolar patients. Precipitation of
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mania may also occur with monomine oxidase inhibitors in
vulnerable people.
Maprotiline is a tetracyclic antidepressant with a predomin-
ant effect on noradrenaline reuptake, and its efficacy in
major depressive illness is similar to that of the standard
antidepressants (Pinto et al, 1972).
Nomifensine, while being a new molecule, has a considerable
amount of activity in common with tricyclics. It does, how-
ever, strongly affect dopamine reuptake as well as noradren-
aline. The drug is inclined to produce insomnia and rest-
lessness. The push on motor activity is of interest in the
context of the present study in view of its dopaminergic
activity. It has been shown to be an effective antidepress-
ant, and to lower the levels of prolactin (McCawley 1979).
There have been claims that nomifensine is also effective in
treating Parkinson's Disease, due to its dopaminergic activ-
ity (Parkes et al, 1977).
3.8.2.3 L-dihydroxyphenylalanine 
Studies on L-dihyroxyphenylalanine in depression are still
problematic, particularly earlier studies where doses of L-
dihydroxyphenylalanine were clearly inadequate. A later
study by Goodwin and his co-workers (1971) with higher dos-
age produced interesting results. Goodwin and co-workers
(1971) found that those depressed patients treated with L-
dihyroxyphenylalanine had an increase of motor activity, but
mood did not appear to be significantly increased.
Patients with Parkinsonism have also been found to be less
depressed after treatment with L-dihyroxyphenylalanine (Cel-
esia and Wanaker, 1972). Mindham et al, (1976) have repor-
ted on the treatment of patients with Parkinson's Disease
and the occurrence of psychiatry morbidity. They found
paradoxically a higher incidence of depressive reactions,
particularly when there had been previous episodes of depres-
sive illness.
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L--dihydroxyphenylalanine is associated with increased incid-
ence of mania and hypomania if given in doses in the region
of 4gm. per day or 400mg. per day with a decarboxylase inhibi-
tor. The risk of a manic attack while on treatment with
L-dihydroxyphenylalanine is much increased if there is a
history of previous manic attacks. The risk of mania is
considerably less in unipolar illness (Bunney Jr. 1978).
While L-dihyroxyphenylalanine increases the incidence of
hypomania in bipolar patients (Murphy 1982, Prien et al,
1973) catecholamine reuptake blockade or monoamine oxidase
inhibition carries a higher risk for the development of
mania in these patients (Bunney Jr. 1978).
3.8.2.4 Drugs Depleting the Brain of Catecholamines 
3.8.2.4.1 Reserpine and Alpha-Methyl-Dihydroxyphenrlalanine
These drugs are associated with a "depletion" of the mono-
amines dopamine and noradrenaline in the brain. Exposure to
reserpine may be associated with depressing effects, which
readily occur in vulnerable people (Bunney Jr. 1978). Pre-
dicting the effects of reserpine is not easy, but clinically
patients on reserpine for hypertension, or as a neuroleptic,
have increased depression as a result of the release of the
amines stored in the nerve terminals.
Both these drugs may be associated with extrapyramidal syn-
dromes, and may potentiate the effects of haloperidol in
the treatment of psychotic patients. A rise of serum pro-
lactin is documented in response to both reserpine and alpha-
methyl-dihydroxyphenylalanine.
Clonidine which is an alpha noradrenergic agonist and pin-
dolol which is a beta blocker, are not associated with rises
in prolactin (Del Pozo and Lancranjam 1978).
The drugs depleting the central nervous system of noradrena-
line, dopamine and 5-hydroxytryptamine are associated with
the induction of depression in vulnerable people. Beta
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blockade has also been reported to produce depression in
some patients, but this requires further study.
3.8.2.4.2 Alpha-Methyl-Para-Tyrosine 
Increased incidence of depression may be associated with the
use of alpha-methyl-para-tyrosine. This substance has been
shown to reduce catecholamine synthesis. Its mode of action
is by inhibition of tyrosine hydroxylase, which is the en-
zyme of the rate limiting step in dopamine synthesis.
There is evidence that alpha-methyl-para-tyrosine is an eff-
ective antimanic agent (Brodie et al, 1971). The clinical
usefulness of alpha-methyl-para-tyrosine is unfortunately
limited by its nephrotoxicity.
3.8.2.5 Lithium
Lithium has multiple effects, including reducing release of
noradrenaline, and facilitating the uptake of noradrenaline
in synaptosomes. This suggests reduced noradrenaline in the
synapse. This is difficult to correlate with the effect on
depression. It appears that only the bipolar depressives
are potentially responsive to lithium. It also interferes
with the development of super-sensitivity of alpha and beta,
adrenergic and dopaminergic receptors. There is good evid-
ence for the effect of lithium on the second messenger sys-
tem (adenylate cyclase system) (Belimaker 1983). All these
effects tend to reduce the functional activity of the cate-
cholamine systems. Support is found here for antimanic ac-
tion, but does not explain the antidepressant effects in a
small number of depressives.
3.8.2.6 Neuroleptics 
The evidence that neuroleptics are effective agents in man-
agement of mania is legion. Haloperidol is one of the most
useful agents in the control of mania, and is a standard
drug in the management of this condition. Virtually all
""),'
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neuroleptics are, however, effective antimanic agents. Chlor-
promazine was for a long time the preferred drug in the
treatment of mania.
The neurotransmitter profiles for neuroleptics are variable,
dopamine, noradrenaline, 5-hydroxytryptamine, histamine and
acetycholine may be involved (Ban 1969). All effective
antimanic neuroleptics must influence the significant neuro-
transmitters in mania, the best candidates are noradrenaline
and dopamine. An increase in noradrenaline function has
generally been favoured as the significant transmitter sys-
tem in mania; an examination of all neuroleptic profiles
in fact favours dopamine (see section on pimozide). The
antimanic effects of lithium probably favours noradrenaline.
The antimanic dopamine component of neuroleptics is probably
mediated by D 2 receptors. A discussion on concentration of
dopamine antagonists at therapeutic doses occurs elsewhere.
Pimozide is of great importance due to its rather specific
dopamine antagonism (Arden et al, 1970). The blocking by
pimozide of noradrenaline receptors seems to be variable
depending on the preparations, but only occurs in high con-
centrations. There is blocking of noradrenaline receptors
and of noradrenaline associated adenylate cyclase at these
high concentrations (supra-therapeutic).
Extrapyramidal effects are relatively reduced due to pimozide
having a fairly high affinity for cholinergic receptors (Yam-
amura et al, 1976).
Post and co-workers reported in 1980 on the effects of pimo-
zide in mania. A small group of patients were shown to
improve on treatment with pimozide, in a similar way to that
associated with response to routinely used phenothiazines
(Post et al, 1980). This report was later supported by
Cookson, Silverstone and Wells (1981).
The efficacy of pimozide in mania increases the support for
the view that dopamine is involved in the pathophysiology of
mania.
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Sulpiride is a drug which has a rather selective dopamine D 2
receptor antagonism. A "pilot" study conducted on fifteen
manic patients suggests that sulpiride in high doses is
effective in mania (Hart 1982). If this is correct the
localisation to a D
2 
receptor will be further strengthened.
A problem with sulpiride is, however, that it affects other
monoamines, i.e. noradrenaline and 5-hydroxytryptamine
included.
Claims that sulpiride is an antidepressant in low doses are
in line with claims that flupenthixol is also an antidep-
ressant at low doses. The possibility being that sulpiride
may have a higher affinity for autoreceptors influencing
neurones via this mechanism. A further possibility is that
the anticholinergic aspects of neuroleptics may be respon-
sible for the antidepressant activity of these drugs.
3.9 CATECHOLAMINE METABOLITES AND PRIMARY AFFECTIVE DISORDERS
3.9.1 Homovanillic Acid
Homovanillic acid is a metabolite of dopamine by deamination
and o-methylation.
The study of homovanillic acid as a means of obtaining indi-
rect information about dopamine appears to have some validity
(Moir et al, 1970). There is controversy about the cerebro-
spinal fluid levels of homovanillic acid in primary affective
disorders. The weight of evidence in the depressive phase
is in favour of lowered levels of homovanillic acid (Goodwin
et al, 1973, Mendels et al, 1973). Elevated levels have
been described in severe mania (Post et al, 1973), but not in
hypomania. This rise in homovanillic acid has been attributed
to the "increased motor activity". The significance of such
a statement requires reconsideration. A study comparing bi-
polar depressives with their manic counterparts showed higher
levels of homovanillic acid in manics compared to the depres-
sives (Bowers 1974). Here the accummulation of homovanillic
acid was investigated using the probenicid technique.
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3.9.2 3-Methoxy-4-Hydroxyphenylglycol 
Both urinary and cerebrospinal fluid 3-methoxy-4-hydroxy-
phenylglycol have been investigated in mania and depression,
Cerebrospinal fluid 3-methoxy-4-hvdroxyphenylglycol appears
not only to be less reliable than urinary 3-methoxy-4-hydr-
oxyphenylglycol, but reported results are so variable that
it is difficult to draw conclusion from them. Urinary
3-methoxy-4-hydroxyphenylglycol will, therefore, be reviewed
in more detail.
Approximately 50% of the urinary 3-methoxy-4-hydroxyphenyl-
glycol is derived from the brain, while the other half
probably occurs as a result of peripheral sympathetic act-
ivity. Lowered urinary 3-methoxy-4-hydroxyphenylglycol
has been reported in depression. On successful treatment
these patients showed an increased output of urinary 3-





The change in 3-methoxy-4-hydroxyphenylglycol
to be related to the amount of agitation, or
these patients (Maas 1973). Bipolar patients
lower levels than unipolar patients (Schild-
This has been found by other workers askraut et al, 1973).
well, for example, Maas.
Tricyclic drugs themselves may have an influence on the
els of 3-methoxy-4-hydroxyphenylglycol which may give rise
to difficulties in interpretation. The physical state of
the patients does not appear to affect the 3-methoxy-4-hyd-
roxyphenylglycol levels materially (Bond et al, 1975).
Depressed bipolar patients appear to excrete decreased quan-
tities of 3-methoxy-4-hydroxyphenylglycol. Unfortunately
not all depressives behave in this fashion. Maas and others
reported that schizophrenic syndromes associated with depres-
sion also seem to have lowered levels of 3-methoxy-4-hydroxy-
phenylglycol (Maas et al, 1969). Those depressives with
lowered 3-methoxy-4-hydroxyphenylglycol responded better to
imipramine and desmethylimioramine, while those with higher
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3-methoxv-4-hydroxyphenylglycol responded less well to these
drugs. Possibly those with higher levels of 3-methoxy-4-
hydroxyphenylglycol respond better to amitriptyline.
3.10 SELF-STIMULATION
There remains much controversy over the significance of self-
stimulation and of the neuronal systems, which support this
behaviour.
The concept of a reward system arises due to the fact that
behaviour, which is associated with stimulation by elect-
rodes placed in certain brain locations, will be repeated in
order to reproduce the stimulation. The behaviour which
results in stimulation appears to be reinforced.
The catecholamines have been widely held to be the trans-
mitter systems involved; much controversy, however, still
remains.
A system which has much support for sustaining self-stimula-
tion is the noradrenergic system, which arises in the locus
coeruleus. The projections run in the dorsal tegmental
noradrenergic bundle. It has been claimed that the greatest
degree of self-stimulation arises from electrodes placed in
areas of highest concentration of catecholaminergic neural
elements (German et al, 1974). This is seen in the path
of the medial forebrain bundle where overlap of the dorsal
noradrenergic bundle, the ventral noradrenergic bundle and
the dopaminergic systems (mesolimbic/cortical and nigro-
striatal) occur (Ungerstedt 1971). Segal and Bloom presented
evidence that stimulation of the locus coeruleus activated the
dorsal noradrenergic bundle and was reinforcing (Segal et al,
1974). Destruction of the dorsal noradrenergic bundle by 6-
hydroxydopamine abolished the response in the hippocampus.
Rewarding effects could occur on activation of the dorsal
noradrenergic bundle with ensuing inhibition of hippocampal
pyramidal cells.
42
There is conflicting evidence surrounding these phenomena
as it is probable that technical factors here led to the
failure by certain groups to obtain self-stimulation from
the locus coeruleus. Clarity has not been obtained as
certain conflicting data exists (Crow et al, 1972).
Destruction of the dorsal noradrenergic bundle does not
abolish the reinforcing effects of locus coeruleus stimula-
tion, nor does damage to the locus coeruleus interfere with
reinforcement from dorsal noradrenergic bundle stimulation
(Crow RAM 1976, Crow TJ 1976). This evidence does not rule
out the dorsal noradrenergic bundle and locus coeruleus in
reinforcement, but certainly casts doubt on it being the
only system involved. Sites which support self-stimulation
certainly lie along the path of the dorsal noradrenergic
bundle.
Crow reported that self-stimulation behaviour with placement
in the locus coeruleus on the one side was associated with
increased 3-methoxy-4-hydroxyphenylglycol on the same side
in the cortex (Crow TJ 1973). This is cited as support for
the coeruleus-cortical noradrenergic system being involved
in self-stimulation behaviour. Dopamine has also been shown
to have increased release in association with self-stimula-
tion.
There is a suggestion from the evidence that catecholamines
are involved in intracranial self-stimulation and that some
differences exist in the functions of dopamine and noradren-
aline in this phenomenon.
Dopamine appears to be associated with driving of behaviour
and noradrenaline seems to be associated with learning and
regulation of behaviour (Ursin et al, 1966). Apomorphine
leads to poorly integrated increased locomotor activity in
normal animals. At high doses sniffing, gnawing etc. occurs
- generally ill-regulated locomotor activity. Amphetamines
produce heightened locomotor activity which is well inte-
grated. This is probably due to mesolimbic, dopaminergic
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involvement (Ungerstedt et al, 1973).
Noradrenergic lesioned animals show little reduction of motor
activity, but on operant tasks they learn much more slowly
and regulation of behaviour is poorer (Ljunberg et al, 1973).
Here the evidence is that the ventral bundle lesion inter-
feres with learning, while the dorsal lesioned animals are
not altered, except under the influence of amphetamine when
they fail to perform.
3.10.1 Hippocampal Self-Stimulation
Areas of highest concentration of noradrenaline do not seem
to support self-stimulation in the hippocampus (Ursin et al,
1966). Stimulation of hippocampal pyramidal cells of C.A.3
area is supporting of self-stimulation and excitatory to
pyramidal cells. The inhibition of other pyramidal cells by
the dorsal noradrenergic system terminals appears to indicate
complex and ill-understood relationships.
3.10.2 Ventral Noradrenergic Bundle 
The degree to which self-stimulation is supported by the
ventral noradrenergic bundle is unclear, and the extent to
which contamination with dopamine elements occurs, remains
to be clarified. Studies certainly have been done, which
suggest that this system may be involved (Ritter et al, 1975).
Evidence that the ventral noradrenergic bundle is involved
in learning was presented by Ljunberg and Ungerstedt (1973).
Lesions of the ventral noradrenergic bundle interfered with
learning. The fact that amphetamines increase locomotor
activity and lead to improved regulation of behaviour, while
apomorphine produces poorly regulated hyperactivity supports
the view that noradrenaline is involved in learning and the
regulation of behaviour.
3.10.3 Dopamine Systems and Self-Stimulation 
Reports that substantia nigra cells support self-stimulation
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remain problematic. The problem being one of overlap with
other systems, for example, noradrenergic and medial fore-
brain bundle elements (Crow TJ 1972). There seems to be
difficulty about separating the effects primarily of norad-
renaline and those of dopamine. Dopaminergic terminals in
the nucleus accumbens have been reported to support self-
stimulation (Phillips et al, 1975).
Critical areas which support self-stimulation appear to be
areas which have dopamine terminals, for example, entorhinal
cortex and cingulate cortex (Collier et al, 1977).
3.10.4 Intracranial Self-Stimulation in Man
Experimental data on intracranial stimulation in man is
understandably limited. Reports on stimulation of the septal
area, mesencephalic tegmentum, amygdala and caudate nucleus
by Heath (1963) constituted the earliest investigations.
Stimulation of the tegmental area was associated with eleva-
tion of mood, while septal effects had a sexual component in
a proportion of electrode placements.
A larger series of patients was reported by Sem-Jacobsen and
Torkildsen (1960). The sites of stimulation were widely
distributed; ventromedial frontal lobe, parietal lobe, tem-
poral lobe, mesencephalon and hypothalamus. Experiences of
"pleasure" could be illicited in many of these areas. The
mid-brain tegmentum, posterior and mid-hypothalamus were
found to support self-stimulation in man (Bishop et al, 1963).
Limitation to stimulation experiments in man are obvious.
Lack of histological confirmation of electrode placement, and
less accurate mapping are to be expected. Nevertheless, areas
which support self-stimulation seem to relate to the cate-
cholamine systems (Nobin and Bjorklund 1973). Much of the
animal experimental work is supported by that carried out in
man. Reinforcement and mood elevation, or pleasure, are
regular companions of intracranial self-stimulation in man.
Here is further evidence that catecholamines are important
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in mood and motor regulation.
3.11 EFFECTS OF DRUGS ON INTRACRANIAL SELF-STIMULATION
3.11.1 Psychoactive Agents 
The drugs which influence intracranial self-stimulation are
those psychoactive agents which influence mood and activity.
These drugs are also very important in primary affective
disorders. The systems involved seem to be closely related
to those systems previously under consideration in the con-
trol of motor activity, motivation and the learning of
behavioural strategy and possibly mood.
3.11.2 Drugs which Depress Catecholamine Function 
Depletion of catecholamines as occurs with reserpine, is
associated with reduction of intracranial self-stimulation.
Interference with the synthesis of catecholamines as occurs
with alpha-methyl-para-tyrosine, attenuates intracranial
self-stimulation.
Blockade of catecholamine post-synaptic receptors reduce
rates of intracranial self-stimulation. Both phenothiazines
and butyrophenones have a profound influence on intracranial
self-stimulation. These are potent antimanic agents. Pimo-
zide has also been reported to significantly reduce self-
stimulation. Certainly the report that pimozide has a strong
influence supports the contention that dopamine is involved
in intracranial self-stimulation (Crow TJ 1973). (See section
on pimozide in mania).
Phenoxybenzamine, is an alpha-adrenergic blocking agent and
has a rather milder effect in reducing intracranial self-
stimulation (Zarevics et al, 1977). Inhibition of dopamine
beta-hydroxylase does not abolish intracranial self-stim-
ulation.
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3.11.3 Drugs which Enhance Catecholamine Function 
Blocking of reuptake of catecholamines from the synaptic
cleft produces good enhancement in intracranial self-stim-
ulation. Cocaine has a powerful enhancing effect, probably
due to catecholamine reuptake blockade. Cocaine produces
euphoria in man. The antidepressants also enhance self-
stimulation, but the reuptake blockade affects a wider range
of neurotransmitters. Randrup and Braestrup (1977) empha-
size the dopamine reuptake blocking of antidepressants. This
appears to be significant with nomifensine, while many other
antidepressants have a considerable action on noradrenaline,
and to a greater or lesser extent, 5-hydroxytryptamine.
Imipramine certainly has a predominant effect on noradrena-
line and enhances intracranial self-stimulation signifi-
cantly.
3.11.3.1 Monoamine Oxidase Inhibitors
The monoamine oxidase inhibitors are associated with de-
creased breakdown of catecholamines by inhibition of the
enzyme monoamine oxidase. Intracranial self-stimulation
is enhanced by this group of drugs which increase catechola-
minergic function.
3.11.3.2 Amphetamines
Amphetamine has a positive effect on intracranial self-stim-
ulation. The modes of action are at least three-fold:-
a) increased release of catecholamine and so increase
availability of catecholamine at the postsynaptic
receptors;
b) a weak monoamine inhibiting action;
c) some blocking effect on reuptake of catecholamines
from the synaptic cleft.
Amphetamines produce an increase in intracranial self-stim-
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ulation whether the electrode placement is in the nucleus
accumbens or in the corpus striatum (Stephens and Herberg,
1977).
3.11.3.3 Dopamine Agonists 
Apomorphine generally increases intracranial self-stimulation
except for a few placements of the electrodes. The dopamin-
ergic system is problematic due to the existence of inhibi-
tory receptors.
3.11.3.4 Bicyclic Agents 
Bicyclic comoounds which are noradrenergic reuptake inhibi-
tors are associated with facilitation of intracranial self-
stimulation, but those drugs associated with 5-hydroxytryp-
tamine function enhancement are associated with attentuation
of intracranial self-stimulation (Sulser 1971).
3.11.4 The Neuronal Substrate of Intracranial Self-
Stimulation
Crow TJ (1973) believes that two systems are involved with
intracranial self-stimulation:-
a) the dopaminergic system with cell bodies in Areas A.9
and A.10, and
b) the noradrenergic system with cells lying in the locus
coeruleus. Stimulation of this system has been shown
to increase the noradrenaline turnover in the ipsilat-
eral cortex (Anlezark et al, 1973).
3.12 ENDOCRINE SYSTEM
3.12.1 Abnormalities of Cortisol Secretion
Increased secretion of cortisol in depressed patients is well
established (Carroll 1972, Carroll et al, 1979). The secre-
tion may be particularly increased in the afternoon and night,
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thus producing a flattened diurnal curve, by comparison with
that occurring in the normal state (Carroll et al, 1979).
This abnormal secretion occurs in about 50% of depressives
and is not a non-specific stress phenomenon. Recovery is
associated with a return to normal (Stokes et al, 1975).
Apart from the hypersecretion of cortisol and adrenocortico-
tropic hormone there is a resistance to suppression with
dexamethasone (Browne et al, 1979). This occurs in slightly
less than 50% of patients who are biologically depressed, or
by Klein's classification "endogenomorphic depressives"
(Klein 1974).
The regulation of cortisol secretion via the hypothalamus
appears to be controlled by excitatory and inhibiting factors.
Cholinergic and serotonergic activity (Scapagnini et al,
1971) have stimulating effects, while noradrenaline (Scapag-
nini et al, 1972) and gabergic functions have inhibitory
effects on corticotropic hormone releasing factor. Defec-
tive noradrenergic mechanisms may be involved in depressives,
resulting in reduced inhibition of corticotropic hormone re-
leasing factor, hence increased levels of adrenocortico-
tropic hormone and cortisol. Cortisol abnormalities are now
well documented in depressive illness, and are considered
here as evidence for possible catecholaminedvsregulation in
primary affective disorder. It also constitutes a prototype
of neuroendocrine testing as a possible means of looking at
neuronal functional integrity in psychiatric disorders.
3.13 ELECTROCONVULSIVE THERAPY
Electroconvulsive therapy is recognised by many authorities
as the most effective treatment of major depressive illness.
Numerous studies bear witness to this including that of West
(1981).
The mode of action of electroconvulsive therapy is of import-
ance in this context. Kett' et al, (1969) demonstrated an in-
creased synthesis and utilization of noradrenaline in the rat
brain after electroconvulsive shock; this was shown in the
49
catecholamine rich areas. The activity of tyrosine hydroxy-
lase was increased (Musacchio et al, 1969) under the influ-
ence of electroconvulsive shock. Beta adrenergic receptors
become less sensitive with multiple electroconvulsive shocks
(Pandey et al, 1979).
Dopamine has also been shown to be affected by electroconvul-
sive therapy, both increases in brain dopamine (Cooper et al,
1968) and in the response of dopamine receptors (Green et al,
1977) have been demonstrated. Cerebrospinal fluid and brain
levels of homovanillic acid were increased by multiple elec-
troconvulsive treatments (Cooper et al, 1968).
Here is further evidence of the possible involvement of both
dopamine and noradrenaline in the therapeutic effects of
electroconvulsive treatment, hence in primary affective dis-
orders.
3.14 DIFFERENTIAL EFFECTS OF ANTIMANIC AGENTS ON MOTOR
ACTIVITY AND MOOD IN MANIA
Evidence of the relative effects of various antimanic agents
on dopamine and noradrenaline can be correlated with effects
on motor activity, and elevation of mood respectively. Res-
erpine acts in a similar fashion on dopamine and noradrena-
line, depletion occurring in both amine stores. Reserpine
influences the course of motor activity and elevated mood in
mania by a parallel reduction in both.
Alpha-methyl-para-tyrosine behaves in a similar manner to
reserpine with a parallel and equal reduction of motor act-
ivity and mood. Alpha-methyl-para-tyrosine "depleted" the
neuronal stores of both dopamine and noradrenaline, without
preference (Brodie et al, 1971).
A number of types of neuroleptics, phenothiazines, butyro-
phenones and diphenylbutylpiperidine have been studied in
detail for the manner in which they reverse the manic state.
The evidence points to a more substantial influence on motor
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activity than on mood. These drugs are more potent dopa-
mine than noradrenaline blocking agents (Goodwin 1979).
Pimozide, in fact, at therapeutic doses, has virtually no
action on noradrenaline, thus it is relatively selective
for dopamine (Anden et al, 1979).
Lithium appears to have a more favourable effect on the aff-
ective component of mania (Goodwin 1979). The effects of
lithium on the catecholamines are discussed. It is diffi-
cult to be sure that noradrenergic effects are greater than
dopaminergic effects, but certainly interference with adeny-
late cyclase seems to favour noradrenaline. Certain of the
other effects also favour noradrenaline. It is, therefore,
possible that the change in mood may correlate with a pre-
dominance of noradrenergic influences rather than of dopa-
mine.
Dopamine-beta-hydroxylase inhibitors may also produce more
profound influence on mood than on motor activity in mania
(Goodwin 1974). Psychotic symptoms appear to worsen with
fusaric acid. This upholds the contention that mood may be
noradrenaline regulated and motor activity (and psychotic
disorganisation) dopamine regulated. Dopamine-beta-hydroxy-
lase inhibition requires further evaluation.
3.15 SUMMARY OF EFFECTS OF PSYCHOACTIVE AGENTS IN
PRIMARY AFFECTIVE DISORDERS
a) Those substances which enhance catecholamine function
in the central nervous system improve depression and
increase the risk of mania in bipolar patients.
b) Those substances which mute central catecholamine
function are associated with increased risk of de-
pression, or an attentuation of mania.
c) Most of the evidence supports this view, despite some
discrepancies which have been reported, for instance
L-dihydroxyphenylalanine producing depression. The
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evidence supporting the view for catecholamine func-
tion being fundamental to the pathophysiology of
primary affective disorders, is greater than for any
other single pathophysiological or psychopathological
view. It is probable that dopamine plays as import-
ant a role in primary affective disorder as does nora-
drenaline, and that their individual dysfunction and
interaction is part of a complex transmitter system
disturbance.
3.16 PROLACTIN
It has been known since 1938 that prolactin is a lactogenic
substance having been found in cow pituitary. The chemistry
of prolactin is very similar to that of growth hormone, these
hormones probably having a common origin. In 1970 evidence
was published that prolactin was separate from growth hor-
mone in human blood (Frantz and Keinberg, 1970). The two
hormones can be easily separated by radioimmunoassay.
Prolactin affects behaviour in more primitive vertebrates
such as birds, in particular reproductive behaviour. There
are two phases the first being sexual, and the second being
the "parenting" or maternal phase. The second phase is pro-
foundly influenced by prolactin. In man very little is
known about its behavioural effects, although its influence
on lactation in "mothering" is well established. There is
also evidence that prolactin is a stress hormone, being sen-
sitive to both physical and psychological stress (Kelly et
al, 1974). This does, of course, make the investigation of
prolactin more difficult and the results more tentative
(Sachar 1965). The study of prolactin may, however, give
information about abnormal events in the nervous system
(Horrobin 1974); not so much because it may be causally re-
lated to the psychiatric condition, but rather in that it
may reflect pathology within the nervous system. It is of
interest that prolactin may stimulate activity of dopamin-
ergic neurones in the limbic and striatal systems, and that
it may interact with the effects of neuroleptics on dopa-
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mine systems (Perkins and Westfall, 1978). There may also
be some effect on acetylcholine. These systems may all be
extremely important in primary affective disorders.
3.16.1 Regulation of Prolactin 
While the regulation of prolactin is complex there are a
few dominant regulatory factors. These may vary with the
state of the person (e.g. post-partum).
3.16.1.1 Negative Control 
Prolactin is able to regulate its own secretion by a short
negative feed-back loop, influencing the tubero-infundibular
dopamine neurones.
3.16.1.2 Tonic Inhibitory Control 
An unusual mode of regulation is by tonic inhibition of
prolactin secretion under the control of the hypothalamus.
Activity of the tubero-infundibular dopaminergic tract de-
creases the secretion of prolactin by the dopaminergic pro-
lactin inhibiting factor. (See section on tubero-hypophy-
seal system and its relation to the portal system.) (Jimenez
et al, 1978).
3.16.1.3 Suckling 
Stimulation of the breast and nipple especially post-partum,
have a profound stimulating effect via the hypothalamus on
the secretion of prolactin.
3.16.1.4 Serotonergic Regulation 




Stress may increase prolactin levels but what the function
of this may be is not understood. The reduction of fertil-
ity under stress may be mediated via this mechanism (Smith
1979).
3.16.1.6 Physiological Factors 
Sleep, exercise, oestrogens and pregnancy may all increase
prolactin levels.
3.16.1.7 Pathological Factors 
A variety of pathological factors may give rise to an in-
crease in prolactin, for instance, hypoglycemia, liver fail-
ure, adenomata, etc.
3.16.1.8 Pharmacological Factors 
Antipsychotic agents which are dopamine antagonists raise
prolactin levels. Chlorpromazine has been used as a chall-
enge for the prolactin system in this study (Kolakowska et
al, 1981.
Reserpine, methyl-dopa, oral contraceptives and thyrotropin
releasing hormone have all been associated with a rise of
prolactin levels in the serum. The reverse effects are
well recorded with apomorphine, L-dihydroxyphenylalanine and
bromocriptine (Aidara et al, 1981).
3.16.1.9 Antidepressants 
No consistent effects on prolactin occur with different
antidepressants. Amitriptyline and imipramine have no eff-
ect. Dibenzepin produces a marked increase in prolactin
by an unknown mechanism. Antidepressant drugs with predom-
inant serotonergic effects tend to produce a rise in pro-
lactin. Zimelidine does not, however, do so. Monoamine
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oxidase inhibitors tend to increase levels of prolactin.
Some inhibition of dopaminergic mechanisms by serotonergic
systems may occur. Nomifensine decreases levels of prolac-
tin. 5-Hydroxytryptamine may produce an increase in pro-
lactin levels. (Meltzer et al, 1978, Meltzer et al, 1979).
3.16.1.10 Electroconvulsive Therapy 
Electroconvulsive therapy has been reported to be associ-
ated with a transitory rise of prolactin. This is presum-
ably due either to the enhancement claimed to occur in
dopaminergic systems, or to the non-specific stress with
electroconvulsive treatment.
3.17 SUBSTANCES ALTERING DEPRESSION AND PROLACTIN LEVELS
Reserpine and alpha-methyl-dopa have been well documented as
being responsible for induction of depression (McKinney and
Kane 1967). These drugs are associated with depletion of
central dopamine and elevation of serum prolactin levels.
The possibility that neuroleptics (dopamine antagonists)
may be associated with the production or promotion of de-
pression has clinical, and some documented, support (McGla-
shan and Carpenter 1976).
There is a suggestion that high doses of certain antidepres-
sants, such as nortriptyline, may be associated with a re-
versal of the normal therapeutic effect (Hollister 1978).
The effect of antidepressants on prolactin is very variable,
and may be dependent on dosage, amine profile of the anti-
depressant, and certain unknown factors. Increased sero-
tonergic activity, due to the effects of serotonergic anti-
depressants may be associated with an increase in prolactin
levels. Dibenzepin has also been reported to produce lac-
torrhoea; the mechanism here is not understood. Nomifen-
sine may reduce prolactin levels by its dopaminergic activity.
Antidepressants are variable in their effects, but do not
generally affect prolactin. They are, of course, able to
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improve the clinical picture of depression.
3.18 ELECTROCONVULSIVE THERAPY AND PROLACTIN IN DEPRESSION
It has been suggested from animal experiments that electro-
convulsive therapy may increase the sensitivity of the post-
synaptic monamine receptors of dopamine, noradrenaline and
5-hydroxytryptamine in the brain (Modigh 1975, Evans and
Modigh 1977). Modigh, Evans and Modigh produced evidence
to support the receptor sensitivity concept of electrocon-
vulsive therapy. Of particular importance is the time
frame, their effects resulted from one electroconvulsive
therapy treatment per twenty four hours and not from hourly
treatment. This reproduces the maximal efficacy of electro-
convulsive therapy when used in treating depressed patients
(Ohman et al, 1976).
Christie and associates studying depressives were unable to
show any change in prolactin levels in response to 0,75mg.
of apomorphine given subcutaneously before, and after,
treatment with electroconvulsive therapy (Christie et al,
1982).
The Skrabanek study looked at the acute effects of electro-
convulsive therapy on prolactin levels, and were able to
show an increase in prolactin 5-24 minutes after treatment
with electroconvulsive therapy. This looks very much like
a stress effect (Skrabanek et al, 1981).
Coppen and associates measured prolactin response to thyro-
tropin releasing hormone in depressed patients. These
workers were unable to find evidence of significant distur-
bance of 5-hydroxytryptamine effects on prolactin. Follow-
ing electroconvulsive therapy the patients showed an in-
creased prolactin sensitivity of central 5-hydroxytrypt-
amine receptors (Coppen et al, 1980).
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3.19 PROLACTIN IN DEPRESSION
Horrobin et al, (1976) reported increased levels of prolactin
in depression, as had Sachar et al, in 1973. The problem of
non-specific stress effects constitutes a difficult problem
to solve. If depressive illness is a complex amine system
interactional disorder it is possible that a sub-group of de-
pressives may show an elevation of prolactin while others may
be normal, or even low. This will be discussed more fully
later in considering dopamine and motor function in depres-
sive illness. Carroll reported an increased secretion of
prolactin in major depressives during the night, this being
abnormally high and not part of the normal diurnal variation
of prolactin secretion. He observed that daytime levels of
prolactin were relatively normal in depressed patients (Hal-
breich et al, 1979).
Meltzer and associates found no abnormalities of prolactin
production in depressives. A conflicting report by Winokur
et al, in 1982 found that prolactin response to thyrotropin
releasing hormone showed a much greater variability, with
both increased and decreased levels being evident. This
may relate to previous comments on the complex nature of the
depressive syndrome (Meltzer et al, 1978).
A study of depressives by Brambilla and associates indicated
a rise of the prolactin response to a thyrotropin releasing
hormone challenge (Brambilla et al, 1981).
Bunney and co-workers reported on effects of beta-2 adrener-
gic stimulation on prolactin levels in depressives. They
found no change at all. Beta-2 adrenergic receptors do not
seem to be involved in the control of prolactin secretion
(Bunney et al, 1981).
Judd and associates using a methadone hydrochloride challenge
found a blunted response of prolactin in depressed patients
and commented that the basal levels were also low! (Judd et
al, 1982)
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Frazer (1975) and Caspar (1977) failed to show an impairment
of growth hormone response to apomorpine in depressed pat-
ients.
3.20 PEPTIDES AND AFFECTIVE DISORDERS
A large number of peptides have been found in the brain and
presumably many play a role in behaviour. The role of pep-
tides in psychiatric disorders is even more obscure. The
response of thyroid stimulating hormone to thyrotropin re-
leasing hormone has been shown to be blunted in a propor-
tion of patients with biological depression (Kirkegaard et
al, 1978). This is now a standard test in affective dis-
order units.
The role of endorphins in affective disorders is unclear.
Endorphins have certainly been shown to produce behavioural
effects similar to the opiates (Koob 1984). Opiate-like
activation is produced when beta-endorphine is injected in-
tra-ventricularly. This action may be related to mesolimbic
dopamine transmission. Endorphins are generally inhibitory
to dopamine inhibition. The role of endorphins and other
peptides in mood and motor regulation requires further in-
vestigation.
3.21 PATHOPHYSIOLOGY IN SCHIZOPHRENIA
Schizophrenia is possibly a hyperdopaminergic state. Crow
has classified schizophrenia into type I and type II, draw-
ing some distinction between the acute active schizophrenics
and the insidious deteriorating schizophrenias. The active
psychotic state, whether schizophrenic or manic, respond
better to neuroleptics than do the so called "negative symp-
tom" schizophrenias of type II, according to Crow (1980).
Antipsychotic effects of neuroleptics have been well related
to their dopamine antagonism (Matthysse 1973). Dopamine an-
tagonism by neuroleptics can be monitored by the measurement
of prolactin. This has been one of the most extensively
studied aspects of prolactin in psychotic disorders (Gruen
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1978). Prolactin increment as a prediction of response of
psychotic states to dopamine antagonists is controversial.
Studies of prolactin in schizophrenia do not support a
hyper-function of the dopamine regulating system of pro-
lactin. It does not seem to reflect the abnormality
(should it exist) in other dopamine systems in schizo-





The difficulty of measuring subtle intracranial events is
self-evident and still remains our greatest challenge. The
present study was conceived in an attempt to investigate
subtle brain function in primary affective disorders. The
probabilities are high that neurobiophysiological disturb-
ances underlie the manifestations of primary affective
disorders; this is strongly supported by previous research
as indicated in Chapter 3.
Much evidence has been reviewed which suggests involvement
of the catecholamines and, in particular dopamine, in primary
affective disorders. The literature review drawer attention to
evidence suggesting the possible involvement of dopamine in
motor behaviour as well as in primary affective disorder.
Disturbance of motor behaviour is fundamental to primary
affective disorders, in particular the bipolar variety! It is
unlikely that the pathology in primary affective disorders
will be found in one system only, but rather a complex inter-
actional disturbance involving a number of systems is likely
to underlie the entire clinical picture.
The emphasis in this study is on dopamine in primary affect-
ive disorders. A fundamental assumption in the formulation
is that the functional state of a dopaminergic system, which
can be indirectly monitored may reflect the disturbance of
less accessible dopamine systems. This possibility can be
assumed as a result of the commonality which exists in dopa-
mine systems. Abnormalities of transmitter function are
probably more likely to be reflected throughout the dopamine
systems of the brain than dysfunction of dopamine receptors.
The heterogeneity of dopamine receptors has been considered
previously, for instance, adenylate cyclase dependent and
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adenylate cyclase nondependent receptors. This heterogeneity
decreases the probability that functional disturbance of the
one type of dopamine receptor will necessarily be reflected
in another type of dopamine receptor.
An attempt is being made to find a change in dopamine func-
tion in primary affective disorders by comparing dopamine
function in well-phase with that of illness-phase. While it
is thought that the mesolimbic and nigrostriatal systems are
more intimately involved with motor function, "measurement"
of these systems remains problematic. The indirectly access-
ible tuberohypophyseal dopamine system was chosen for investi-
gation. It is hoped that this system may demonstrate changes
in primary affective disorders that reflect similar dysfunc-
tion in the motor dopamine system.
4.2 THE EXPERIMENTAL SYSTEM
Dopamine profoundly regulates prolactin as has been stated
previously (Jimenex et al, 1978). Investigation of the dopa-
mine/prolactin axis has a real possibility of reflecting the
state of other intracranial dopamine systems. The dopamine
receptors involved in prolactin regulation have been reviewed;
dopamine exerting an inhibitory influence on prolactin secre-
tion. Dopaminergic systems may be abnormal in primary affective
disorders (Post et al, 1980). Dopamine receptors regulating
prolactin have much in common with D
2 
receptors and are probab-
ly variants of D 2 receptors. This means that there is a fairly
strong similarity between the test system and putative motor
drive system. The choice of a challenge technique for the in-
vestigation of the dopamine prolactin axis was influenced by
the fact that the prolactin system is very responsive to stress.
It was thought, therefore, that a challenge would possibly
produce more reliable results. A further factor was that a
challenge would probably put the system under stress and there-
fore may demonstrate deviations not seen in an unstressed
situation. Rapid fluctuations of prolactin which may occur at
rest reduce the reliability of these readings. It is postulated
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that the "stressed" system is more likely to produce a con-
sistent pattern of response.
The pharmacological challenge was conducted in two parts,
the one being when the patient was ill, and the other when
the patient was well or significantly improved.
Two agents were used in the actual challenge investigation
which was conducted on two separate days. The first agent
being L-dihydroxyphenylalanine which was given orally in a
single dose of 500mg. on the first day. L-dihydroxyphenyl-
alanine enhances dopaminergic activity and is associated
with an increased inhibition of prolactin secretion. The
second agent to which the patient was exposed was chlorpro-
mazine, a dose of 25mg. by intramuscular injection being
given. This drug blocks dopamine thereby reducing the tonic
dopaminergic inhibition on prolactin with a resultant in-
creased secretion. Details of the procedure are recorded
later, but of primary importance is the fact that this pro-
cedure was conducted when the patient was ill and when the
patient was recovered or significantly improved.
4.3. SUBJECTS
4.3.1 Selection
The subjects for this study were drawn from admission to the
Biological Unit at Tara - The H. Moross Centre. Patients with
physical disease or pregnancy were excluded. No patients
under the age of sixteen years were included. Informed con-
sent was a prerequisite.
A full psychiatric investigation and evaluation was conducted
including the patients' history and mental state examination.
Further information was obtained regarding the patients'
social/occupational milieu, previous psychiatric records,
psychological testing and observation.
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A diagnostic formulation for inclusion/exclusion was based
on the Diagnostic and Statistical Manual of Mental Disorders
(DSM III) of the American Psychiatric Association. The diag-
nostic criteria were those appropriate for primary affective
disorders.
4.3.2 Diagnostic Criteria
The following are the diagnostic criteria for primary affect-
ive disorders according to the DSM III:-
"Diagnostic criteria for major depressive episode
A. Dysphoric mood or loss of interest or pleasure in all or
almost all usual activities and pastimes. The dysphoric mood
is characterized by symptoms such as the following: depressed,
sad, blue, hopeless, low, down in the dumps, irritable. The
mood disturbance must be prominent and relatively persistent,
but not necessarily the most dominant symptom, and does not
include momentary shifts from one dysphoric mood to another
dysphoric mood, e.g., anxiety to depression to anger, such as
are seen in states of acute psychotic turmoil. (For children
under six, dysphoric mood may have to be inferred from a per-
sistently sad facial expression).
B. At least four of the following symptoms have each been
present nearly every day for a period of at least two weeks
(in children under six, at least three of the first four).
(1) poor appetite or significant weight loss (when not
dieting) or increased appetite or significant weight gain
(in children under six, consider failure to make expected
weight gain)
(2) insomnia or hypersomnia
(3) psychomotor agitation or retardation (but not merely
subjective feelings of restlessness or being slowed down)
(in children under six, hypoactivity)
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(4) loss of interest or pleasure in usual activities
or decrease in sexual drive not liiilited to a period when
delusional or hallucinating (in children under six, signs
of apathy)
(5) loss of energy; fatigue
(6) feelings of worthlessness, self-reproach, or excessive
or inappropriate guilt (either may be delusional)
(7) complaints of evidence of diminished ability to think
or concentrate, such as slowed thinking, or indecisiveness
not associated with marked loosening of associations or
incoherence
(8) recurrent thoughts of death, suicidal ideation, wishes
to be dead, or suicide attempt
C. Neither of the following dominate the clinical picture
when affective syndrome (i.e., criteria A and B above) is
not present, that is, before it developed or after it was
remitted:
(1) preoccupation with a mood-congruent delusion or hallu-
cination (see definition below)
(2) bizarre behaviour
D. Not superimposed on either Schizophrenia, Schizophreni-
form Disorder, or a Paranoid Disorder.
E. Not due to any Organic Mental Disorder or Uncomplicated
Bereavement.
Fifth-digitcode numbers and criteria for subclassification
of major depressive episode
(When psychotic features and Melancholia are present the
coding system requires that the clinician record the single
most clinically significant characteristic.) .
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(b) the depression is regularly worse in the morning
(c) early morning awakening (at least two hours before
usual time of awakening)
(d) marked psychomotor retardation or agitation
(e) significant anorexia or weight loss
(f) excessive or inappropriate guilt
2- Without Melancholia
0- Unspecified
Diagnostic criteria for a manic episode
A. One or more distinct periods with a predominantly elevated,
expansive, or irritable mood. The elevated or irritable mood
must be a prominent part of the illness and relatively per-
sistent, although it may alternate or intermingle with depres-
sive mood.
B. Duration of at least one week (or any duration if hospital-
ization is necessary), during which, for most of the time, at
least three of the following symptoms have persisted (four if
the mood is only irritable) and have been present to a signi-
ficant degree:
(1) increase in activity (either socially, at work, or sexual-
ly) or physical restlessness
(2) more talkative than usual or pressure to keep talking
(3) flight of ideas or subjective experience that thoughts
are racing
(4) inflated self-esteem (grandiosity, which may be delusional)
(5) decreased need for sleep
(6) distractability, i.e., attention is too easily drawn to
unimportant or irrelevant external stimuli
(7) excessive involvement in activities that have a high
potential for painful consequences which is not recognized,
e.g., buying sprees, sexual indiscretions, foolish business
investments, reckless driving
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C. Neither of the following dominate the clinical picture
when an affective syndrome (i.e., criteria A and B above) is
not present, that is, before it developed or after it has
remitted:
(1) preoccupation with a mood-congruent delusion or hallu-
cination (see definition below)
(2) bizarre behaviour
D. Not superimposed on either Schizophrenia, Schizophreni-
form Disorder, or a Paranoid Disorder.
E. Not due to any Organic Mental Disorder, such as Substance
Intoxication.
(Note: A hypomanic episode is a pathological disturbance
similar to, but not as severe as, a manic episode.
Fifth-digit code numbers and criteria for subclassification
of manic episode
6- In Remission. This fifth-digit category should be used
when in the past the individual met the full criteria for a
manic episode but now is essentially free of manic symptoms
or has some signs of the disorder but does not meet the full
criteria. The differentiation of this diagnosis from no
mental disorder requires consideration of the period of time
since the last episode, the number of previous episodes, and
the need for continued evaluation of prophylactic treatment.
4- With Psychotic Features. This fifth-digit category should
be used when there apparently is gross impairment in reality
testing, as when there are delusions or hallucinations or
grossly bizarre behavior. When possible, specify whether the
psychotic features are mood-congruent. (The non-ICD-9-CM fifth-
digit 7 may be used instead to indicate that the psychotic
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features are mood-congruent; otherwise, mood-congruence may
be assumed.)
Mood-congruent Psychotic Features: Delusions or hallucinations
whose content is entirely consistent with the themes of in-
flated worth, power, knowledge, identity, or special relation-
ship to a deity or famous person; flight of ideas without
apparent awareness by the individual that the speech is not
understandable.
Mood-incongruent Psychotic Features: Either (a) or (b):
(a) Delusions or hallucinations whose content does not involve
themes of either inflated worth, power, knowledge, identity,
or special relationship to a deity or famous person. Included
are such symptoms as persecutory delusions, thought insertion,
and delusions of being controlled, whose content has no
apparent relationship to any of the themes noted above.
(b) Any of the following catatonic symptoms: stupor, mutism,
negativism, posturing.
2- Without Psychotic Features. Meets the criteria for manic
episode, but no psychotic features are present.
0- Unspecified.
Diagnostic criteria for Bipolar Disorder, Mixed
Use fifth-digit coding for manic episode.
A. Current (or most recent) episode involves the full sympto-
matic picture of both manic and major depressive episodes
intermixed or rapidly alternating every few days.
B. Depressive symptoms are prominent and last at least a full
day.
Diagnostic criteria for Bipolar Disorder, Manic
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Currently (or most recently) in a manic episode. (If there
has been a previous manic episode, the current episode need
not meet the full criteria for a manic episode).
Diagnostic criteria for Bipolar Disorder, Depressed
A. Has had one or more manic episodes.
B. Currently (or most recently) in a major depressive episode.
(If there has been a previous major depressive episode, the
current episode of depression need not meet the full criteria
for a major depressive episode.)
Diagnostic criteria for Major Depression
A. One or more major depressive episodes.
B. Has never had a manic episode or hypomanic episode."
4.4. METHODS
4.4.1 Experimental Procedures 
Once the subjects had been accepted into the study having
duly considered the exclusion and inclusion criteria, they
were subjected to a standardised programme.
4.4.2 Wash-Out Period
All patients who, prior to admission, had been on psychotropic
agents were withdrawn from these drugs. Those patients who
were very agitated or sleepless were allowed limited doses of
oxazepam, particularly at night. A 7-10 day wash-out period
was observed. This was common practice within the unit under
normal circumstances. Those subjects who had not been on
psychoactive aaents prior to admission were permitted virtual-
ly direct admission to the study, once the evaluative process
had been completed and inclusion accepted.
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4.4.3 Rating 
A rating of the subject's mental state was carried out prior
to the first pharmacological challenge. The rating scales
used were the Hamilton Depressive Rating in the majority of
patients and the Pettersen Scale of Mania was used in the
presence of hypomania and mania. The rating was repeated
prior to the second pharmacological challenge. Thus two lots
of rating values were obtained, those when the subject was
ill, "illness score" and those when the subject was well, or
significantly recovered, "well score".
4.4.4 Treatment
Depressed subjects were treated by conventional means, the
majority having received electroconvulsive therapy, while a
small proportion were given antidepressants. The standard
antidepressant used was maprotiline, although one subject
was treated with nomifensine due to her poor tolerance of
maprotiline. Manic patients were treated with haloperidol.
The second pharmacological challenge was conducted a minimum
of two weeks after the withdrawal of haloperidol.
4.4.5 The Challenge Procedure
The technique for both "ill" and "well" challenges was identi-
cal. The investigation was conducted under fasting conditions,
no food having been taken from 22h00 on the previous day. All
procedures were carried out in the morning between 08h00 and
09h00.
4.4.5.1 L-dihydroxyphenylalanine Challenge (Day 1)
The subject was exposed to L-dihydroxyphenylalanine on Day 1.
An intravenous line was set up and the base-line blood was
taken following which 500mgs. of L-dihydroxvphenylalanine was
administered orally. Four subsequent blood samples were taken
at 20, 40, 60, 90 minutes after the administration of
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L-dihydroxyphenylalanine.
4.4.5.2 Chlorpromazine Challenge (Day 2)
24 - 72 hours after the L-dihydroxyphenylalanine challenge
the subjects were exposed to chlorpromazine 25mgs. intramus-
cularly. This chlorpromazine technique was similar to that of
the L-dihydroxyphenylalanine challenge, the blood samples
being a baseline sample and five subsequent samples at 20, 40,
60, 90, 120 minute intervals from the time of administration
of the chlorpromazine.
All the blood was immediately centrifuged and the serum sepa-
rated and frozen at -20C, under which conditions it was stored
until assay for prolactin was carried out in batches. All
samples were appropriately labelled and dated.
The pharmacological challenges were repeated upon significant
improvement. Two sets of prolactin readings for each of the
L-dihydroxyphenylalanine and chlorpromazine challenges were
obtained giving a set of readings for "illness" phase and a
set for "well" phase.
4.4.6 The Final Data
The final data containing the relevant variables was therefore
constituted in the following way:-
4.4.6.1 "Illness" Phase Data
This data was made up of a set of ratings (Hamilton/Pettersen)
and a set of prolactin values in response to the L-dihydroxy-
phenylalanine and chlorpromazine challenges.
4.4.6.2 "Well"Phase Data
The "well"phase data also consisted of a set of ratings
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(Hamilton/Pettersen) and a set of prolactin values in res-
ponse to the L-dihydroxyphenylalanine and chlorpromazine
challenges, these measures having been conducted after
significant improvement had occurred.
Two subjects were studied in a depressed (illness) phase and
also in manic (illness) phase, as well as recovered (well)
phase.
4.4.6.3 Other Variables
A number of other variables were considered in the statisti-






Examples of the rating scales and prolactin values can be
seen in the raw data.
4.5 PROLACTIN ASSAY BY RADIOIM.MUNOASSAY KIT (RIANEN ASSAY
SYSTEM)
A radioimmunoassay technique was used to measure the levels
of plasma prolactin. The principle of the assay is based upon
competition between radioactive labelled antigen and non-
labelled antigen (prolactin) for a fixed number of specific
antibody binding sites.
A constant and limiting amount of antibody is used and allowed
to react with a constant amount of labelled antigen and with
samples or standards (unlabelled antigen). The amount of
labelled antigen re-acting with the antibody decreases as the
quantity of unlabelled antigen, sample or standard, is
72
increased. If the antibody antigen complex is separated from
the unbound tracer the bound radioactive label complex can
be counted. Standards may be used to construct a curve from
which the values of samples can be obtained.
Separation of the bound from the free antigen is achieved by
precipitation of the antigen-antibody complex by the addi-
tion of a second antibody which has been developed from the
gamma globulin of the primary antibody, in a different
species of animal. Precipitation is followed by incubation
and centrifugation, and supernatant being discarded.
4.5.1 Primary Antibody
The prolactin antibody (developed in rabbit) is supplied in
a vial and stored at 4 ° C.
4.5.2 Labelled Antigen
A vial of prolactin with radioactive tracer is supplied with
the kit and has to be accurately reconstituted with distilled
water and stored at 4°C. Precautions in handling this
material must be observed and it is not to be used for any
in vivo study. Observation of all restrictions were observed
as pertinent to this particular material.
4.5.3 Prolactin Standards
Standards of prolactin are supplied with the kit and have to
be accurately reconstituted with distilled water. Seven stand-
ards are provided ranging from 0, 5, 10, 20, 100 to 200ng/ml.
This is standard human prolactin in buffer. Storage at 4°C.
4.5.4 Blank Antiserum
Vials of normal rabbit antiserum forms part of the kit.
Storage observed at 4°C.
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4.5.5 Control Serum
Human serum with a prolactin concentration of 25ng/ml is
supplied. This must be reconstituted as indicated with
exactly 1 ml of distilled water and stored at 4°C.
4.5.6 Second Antibody
The second antibody is supplied ready for use and stored at






The raw data on twenty seven cases is presented. This data
comprises of two groups of subjects, those who were investi-
gated and rated in the depressive phase, and the second
group which was investigated and rated in the manic phase.
Both groups were re-rated and investigated upon recovery.
Standard rating scales were used for scoring, the Hamilton
Depressive Scale for the depressive phase and the Pettersen
Scale for the manic phase. The actual raw data is included
for all twenty seven patients. Twenty one subjects were
rated on the Hamilton Scale and eight subjects were rated on
the Pettersen Scale giving an effective total of twenty nine
sets of raw data. Two subjects were investigated both when
manic and depressed. The investigations performed were those
previously discussed being pharmacological challenges with
L-dihydroxyphenylalanine and chlorpromazine; blood sampling
for prolactin was carried out at times 0 (baseline) 20, 40,
60, 90 minutes and an additional sample at 12G minutes for
the chlorpromazine challenge. These times are represented
in Tables LXXXIX - XLII by the symbols B, C, D, E, F and G
respectively.
The raw data presented are the actual values of prolactin for
baseline levels and levels at the times indicated in the data
sheets, before and after treatment (i.e. "ill" values and
"well" values). The discrepancy between the twenty seven
subjects and the twenty nine sets of raw data is due to the
two subjects who were investigated both when depressed and
when manic. The two sets of data for each of these two sub-
jects were dealt with as four separate subjects. The reasons
for this are that the number of patients investigated (two)
in both phases of bipolar illness is too small to produce
significant results, and limitation of the rating instrum-
ments do not allow ease of comparison of data through from
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depressed to manic phase. Some further comments on these
two patients will, however, be made at a later stage.
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PATIENT IDENTIFICATION: 1 SEX: F AGE: 68












1. DEPRESSED MOOD 0 - 4 3 0
2. FEELING OF GUILT 0 - 4 2 0
3. SUICIDE 0 - 4 1 0
4. INSOMNIA - EARLY 0 - 2 0 1
5. INSOMNIA - MIDDLE 0 - 2 0 0
6. INSOMNIA - LATE 0 - 2 2 1
7. WORK AND ACTIVITIES 0 - 4 2 0
8. RETARDATION 0 - 4 3 0
9. AGITATION 0 - 2 1 0
10. ANXIETY PSYCHIC 0 - 4 3 1
11. ANXIETY - SOMATIC 0 - 4 1 0
12. ANXIETY SYMPTOMS (G.I.T.) 0 - 2 0 0
13. SOMATIC SYMPTOMS (GEN) 0 - 2 0 0
14. GENITAL SYMPTOMS 0 - 2 0 0
15. HYPOCHONDRIASES 0 - 4 0 0
16. LOSS OF WEIGHT 0 - 2 2 1
17. INSIGHT 0 - 2 0 0
18. DIURNAL VARIATION 0 - 2 0 0
19. DEPERSONALISATION 0 - 4 1 0
20. PARANOID SYMPTOMS 0 - 4 0 0
21. OBSESSIONAL SYMPTOMS 0 - 2 1 1
22. HELPLESSNESS 0 - 4 2 0
23. HOPELESSNESS 0 - 4 3 1
24. WORTHLESSNESS 0 - 4 3 0
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PATIENT IDENTIFICATION: 1 SEX: F AGE: 68




SERUM PROLACTIN VALUES IN ng/ml.
L-DIHYDROXYPHENYLALANINE CHALLENGE
TIME IN MINUTES "ILL" VALUES I "WELL" VALUES
0 0.3 4.7
20 0 1.6
40 0 3 2.1
60 0 4.2
90 0 2 .0
TABLE III
CHLORPROMAZINE CHALLENGE




60 i 1 5.5 13.3
90 8.7 i 13.4
120 14.7
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PATIENT IDENTIFICATION: 3 SEX: F AGE: 59
DIAGNOSIS: PRIMARY AFFECTIVE DISORDER - BIPOLAR
PHASE: DEPRESSED
TREATMENT: ELECTROCONVULSIVE THERAPY AND
ANTIDEPRESS2NNTS
TABLE IV








1. DEPRESSED MOOD 0 - 4 3 1
2. FEELING OF GUILT 0 - 4 2 0
i 3. SUICIDE 0 - 4 1 0
4. INSOMNIA - EARLY 0 - 2 1 1
5. INSOMNIA - MIDDLE 0 - 2 1 0
6. INSOMNIA - LATE 0 - 2 1 0
7. WORK AND ACTIVITIES 0 - 4 3 0
8. RETARDATION 0 - 4 0 0
9. AGITATION 0 - 2 2 1
10. ANXIETY PHYSIC 0 - 4 3 2
11. ANXIETY - SOMATIC 0 - 4 2 1
12. ANXIETY SYMPTOMS (G.I.T.) 0 - 2 1 1
13. SOMATIC SYMPTOMS (GEN) 0 - 2 1 0
14. GENITAL SYMPTOMS 0 - 2 0 0
15. HYPOCHONDRIASES 0 - 4 1 0
16. LOSS OF WEIGHT 0 - 2 1 0
17. INSIGHT 0 - 2 1 i 0
18. DIURNAL VARIATION 0 - 2 2 0
19. DEPERSONALISATION 0 - 4 1 0
20. PARANOID SYMPTOMS 0 - 4 0 0
21. OBSESSIONAL SYMPTOMS 0 - 2 1 1
22. HELPLESSNESS 0 - 4 2 0
23. HOPELESSNESS 0 - 4 3 1
24. WORTHLESSNESS 0 - 4 2 0
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PATIENT IDENTIFICATION: 3 SEX: F AGE: 59
DIAGNOSIS: PRIMARY AFFECTIVE DISORDER - BIPOLAR
PHASE: DEPRESSED
TREATMENT: ELECTROCONVULSIVE THERAPY AND
ANTIDEPRESSANTS
TABLE V
SERUM PROLACTIN VALUES IN ng/ml.
L-DIHYDROXYPHENYLALANINE CHALLENGE








TIME IN MINUTES "ILL" VALUES "WELL" VALUES







PATIENT IDENTIFICATION: 4 SEX: M AGE: 66











1. DEPRESSED MOOD 0 - 4 2 0
2. FEELING OF GUILT 0 - 4 0 0
3. SUICIDE 0 - 4 0 0
4. INSOMNIA - EARLY 0 - 2 0 0
5. INSOMNIA - MIDDLE 0 - 2 0 0
6. INSOMNIA - LATE 0 - 2 1 1
7. WORK AND ACTIVITIES 0 - 4 2 1
8. RETARDATION 0 - 4 2 0
9. AGITATION 0 - 2 0 0
10. ANXIETY PSYCHIC 0 - 4 2 1
11. ANXIETY - SOMATIC 0 - 4 0 0
12. ANXIETY SYMPTOMS (G.I.T.) 0 - 2 1 0
13. SOMATIC SYMPTOMS (GEN) 0 - 2 0 0
14. GENITAL SYMPTOMS 0 - 2 1 0
15. HYPOCHONDRIASES 0 - 4 1 1
11 6. LOSS OF WEIGHT 0 - 2 1 0
17. INSIGHT 0 2 0 0
18. DIURNAL VARIATION 0 2 1 0
19. DEPERSONALISATION 0 - 4 0 0
20. PARANOID SYMPTOMS 0 - 4 0 0
21. OBSESSIONAL SYMPTOMS 0 - 2 1 1
22. HELPLESSNESS 0 - 4 1 0 4
23. HOPELESSNESS 0 - 4 1 0 I
24. WORTHLESSNESS 0 - 4 0 0 I
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PATIENT IDENTIFICATION: 4 SEX: M AGE: 66




SERUM PROLACTIN VALUES IN ng/ml.
L-DIHYDROXYPHENYLALANINE CHALLENGE

















PATIENT IDENTIFICATION: 5 SEX: M AGE: 47










1. DEPRESSED MOOD 0 - 4 2 0
2 FEELING OF GUILT 0 - 4 C 0
3. SUICIDE 0 - 4 0 0
4. INSOMNIA - EARLY 0 - 2 1 1
5. INSOMNIA - MIDDLE 0 - 2 0 0
6. INSOMNIA - LATE 0 - 2 1 1
7. WORK AND ACTIVITIES 0 - 4 2 0
8. RETARDATION 0 - 4 1 0
9. AGITATION 0 - 2 1 0
10. ANXIETY PSYCHIC 0 - 4 2 1
11. ANXIETY - SOMATIC 0 4 0 0
• 2. ANXIETY SYMPTOMS (G.I.T.) 0 - 2 0 0
1 1 3. SOMATIC SYMPTOMS (GEN) 0 - 2 1 0
14. GENITAL SYMPTOMS 0 - 2 1 0
I05. HYPOCHONDRIASES 0 - 4 j 0 0
16. LOSS OF WEIGHT 0 - 2 1 2 1
17. INSIGHT 0 - 2 0 i 0
18. DIURNAL VARIATION 0 - 2 0 I 0
h9. DEPERSONALISATION 0 - 4 1 0 0
,
20. PARANOID SYMPTOMS 0 0
21. OBSESSIONAL SYMPTOMS 0 - 2 0 0
1
22. HELPLESSNESS 0 - 4 0 0
23. HOPELESSNESS 0 - 4 1 1
124. WORTHLESSNESS 0 - 4 1 0
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PATIENT IDENTIFICATION: 5 SEX: M AGE: 47




SERUM PROLACTIN VALUES IN ng/ml.
L-DIHYDROXYPHENYLALANINE CHALLENGE
TIME IN MINUTES "ILL" VALUES "WELL" VALUES















PATIENT IDENTIFICATION: 6 SEX: F AGE: 75










1. DEPRESSED MOOD 0 - 4 3 1
2. FEELING OF GUILT 0 - 4 0 0
3. SUICIDE 0 - 4 1 1 0
4. INSOMNIA - EARLY 0 - 2 0 0
5. INSOMNIA - MIDDLE 0 - 2 0 0
6. INSOMNIA - LATE 0 - 2 1 1
7. WORK AND ACTIVITIES 0 - 4 I 2 1
8. RETARDATION 0 - 4 0 0
9. AGITATION 0 - 2 1 2 0
10. ANXIETY PSYCHIC 0 - 4 2 1
11. ANXIETY SOMATIC 0 - 4 0 0
12. ANXIETY SYMPTOMS (G.I.T.) 0 - 2 2 1
13. SOMATIC SYMPTOMS (GEN) 0 - 2 0 0
14. GENITAL SYMPTOMS 0 - 2 0 0
15. HYPOCHONDRIASES 0 - 4 1 0 0
16. LOSS OF WEIGHT 0 - 2 i 1 0
17. INSIGHT 0 - 2 C 0 t 0
18. DIURNAL VARIATION 0 - 2 1 2 1
19. DEPERSONALISATION 0 - 4 1 0 0
20. PARANOID SYMPTOMS 0 - 4 0 I 0
21. OBSESSIONAL SYMPTOMS 0 - 2 2 1
22. HELPLESSNESS 0 - 4 2 0
23. HOPELESSNESS 0 - 4 2 1 1
24. WORTHLESSNESS 0 - 4 1
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PATIENT IDENTIFICATION: 6 SEX: F AGE: 75
DIAGNOSIS: PRIMARY AFFECTIVE DISORDER - UNIPOLAR
TREATMENT: ELECTROCONVULSIVE THERAPY
TABLE XIV
SERUM PROLACTIN VALUES IN ng/ml.
L-DIHYDROXYPHENYLALANINE CHALLENGE








TIME IN MINUTES "ILL" VALUES "WELL" VALUES
0 1 0.7 22.9
20 9.9 14.7
40 10.0 1 2.0
60 9.1 14.4
90 11.9 17.1
1 20 16.2 i 1 8.9
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PATIENT IDENTIFICATION : 7 SEX: F AGE: 67











1. DEPRESSED MOOD 0 - 4 3 1
2. FEELING OF GUILT 0 - 4 3 0
3. SUICIDE 0 - 4 3 0
4. INSOMNIA - EARLY 0 - 2 1 0
5. INSOMNIA - MIDDLE 0 - 2 1 0
6. INSOMNIA - LATE 0 - 2 2 1
. WORK AND ACTIVITIES 0 - 4 1
8. RETARDATION 0 - 4 3 0
9. AGITATION 0 - 2 0 0
10. ANXIETY PSYCHIC 0 - 4 2 1
11. ANXIETY - SOMATIC 0 - 4 0 0
12. ANXIETY SYMPTOMS (G.I.T.) 0 - 2 1 0
13. SOMATIC SYMPTOMS (GEN) 0 - 2 0 0
14. GENITAL SYMPTOMS 0 - 2 2 1
15. HYPOCHONDRIASES 0 - 4 1 0
16. LOSS OF WEIGHT 0 - 2 1 0
17. INSIGHT 0 - 2 1 2 0
18. DIURNAL VARIATION 0 - 2 2 0
19. DEPERSONALISATION 0 - 4 3 0
20. PARANOID SYMPTOMS 0 - 4 0 0
21. OBSESSIONAL SYMPTOMS 0 - 2 0 2
22. HELPLESSNESS 0 - 4 3 1
23. HOPELESSNESS 0 - 4 3 0
24. WORTHLESSNESS 0 - 4 4 1
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PATIENT IDENTIFICATION: 7 SEX: F AGE: 67
DIAGNOSIS: PRIMARY AFFECTIVE DISORDER - BIPOLAR
TREATMENT: ELECTROCONVULSIVE THERAPY
TABLE XVII
SERUM PROLACTIN VALUES IN ng/ml
L-DIHYDROXYPHENYLALANINE CHALLENGE














1 20 1 3.8 41.5
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PATIENT IDENTIFICATION: 8 SEX: F AGE: 41












1. DEPRESSED MOOD 0 - 4 3 0
2. FEELING OF GUILT 0 - 4 1 1
3. SUICIDE 0 - 4 2 0
4. INSOMNIA - EARLY 0 - 2 2 1
5. INSOMNIA - MIDDLE 0 - 2 1 0
6. INSOMNIA - LATE 0 - 2 2 0
7. WORK AND ACTIVITIES 0 - 4 2 1
0. tt.rliktUJA.LION U - 4 I U
9. AGITATION 0 - 2 2 0
10. ANXIETY PSYCHIC 0 - 4 3 2
11. ANXIETY - SOMATIC 0 - 4 1 0
12. ANXIETY SYMPTOMS (G.I.T.) 0 - 2 1 1
13. SOMATIC SYMPTOMS (GEN) 0 - 2 0 0
14. GENITAL SYMPTOMS 0 - 2 1 0
15. HYPOCHONDRIASES 0 - 4 0 0
16. LOSS OF WEIGHT 0 - 2 1 0
17. INSIGHT 0 - 2 j 0 0
18. DIURNAL VARIATION 0 - 2 i 1 0
19. DEPERSONALISATION 0 - 4 0 0
20. PARANOID SYMPTOMS 0 - 4 1 0
21. OBSESSIONAL SYMPTOMS 0 - 2 0 1
22. HELPLESSNESS 0 - 4 2 0
23. HOPELESSNESS 0 - 4 2 1
24. WORTHLESSNESS 0 - 4 2 1
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PATIENT IDENTIFICATION: 8 SEX: F AGE: 41




SERUM PROLACTIN VALUES IN ng/ml.
L-DIHYDROXYPHENYLALANINE CHALLENGE
TIME IN MINUTES "ILL" VALUES "WELL" VALUES
0 12.7 10.1











90 26.5 i 18.0
120 I 35.4
90
PATIENT IDENTIFICATION: 9 SEX: F AGE: 54











1. DEPRESSED MOOD 0 - 4 3 1
2. FEELING OF GUILT 0 - 4 2 0
3. SUICIDE 0 - 4 0 0
4. INSOMNIA - EARLY 0 - 2 1 0
5. INSOMNIA - MIDDLE 0 - 2 0 0
i 6. INSOMNIA - LATE 0 - 2 1 0
7. WORK AND ACTIVITIES 0 - 4 3 0
8 RETARDATION 0 - 4 3 0
9 	AGITATION 0 - 2 2 i 1
MO. ANXIETY PSYCHIC 0 - 4 2 0
ANXIETY - SOMATIC 0 - 4 2 0
12. ANXIETY SYMPTOMS (G.I.T.) 0 - 2 i 0 0
M3. SOMATIC SYMPTOMS (GEN) 0 - 2 1 0
04. GENITAL SYMPTOMS 0 - 2 2 0
h
5. HYPOCHONDRIASES 0 - 4 2 0
16. LOSS OF WEIGHT 0 - 2 1 0 0
17. INSIGHT 0 - 2 1 1
18. DIURNAL VARIATION 0 - 2 j 0 0
19. DEPERSONALISATION 0 - 4 0 0
20. PARANOID SYMPTOMS 0 - 4 0 0 I
21. OBSESSIONAL SYMPTOMS 0 - 2 0 0
22. HELPLESSNESS 0 - 4 2 0
23. HOPELESSNESS 0 - 4 3 0
24. WORTHLESSNESS 0 - 4 2 1
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PATIENT IDENTIFICATION: 9 SEX: F AGE: 54




SERUM PROLACTIN VALUES IN ng/ml.
L-DIHYDROXYPHENYLALANINE CHALLENGE












60 0 1 4.8
90 0.9
1 20 3.1 21.6
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PATIENT IDENTIFICATION: 10 SEX: F AGE: 48









SCORE   
1. DEPRESSED MOOD 0 - 4 2 1
2. FEELING OF GUILT 0 - 4 0 0
3. SUICIDE 0 - 4 2 0
4. INSOMNIA - EARLY 0 - 2 1 1
5. INSOMNIA - MIDDLE 0 - 2 1 0
6. INSOMNIA - LATE 0 - 2 1 0
7. WORK AND ACTIVITIES 0 - 4 2 1
8. RETARDATION 0 - 4 0 0
9. AGITATION 0 - 2 0 0
]U. ANXIETY PSYCHIC U - 4 2 2
11. ANXIETY - SOMATIC 0 - 4 0 0
12. ANXIETY SYMPTOMS (G.I.T.) 0 - 2 1 1
1 3. SOMATIC SYMPTOMS (GEN) 0 - 2 1 0
14. GENITAL SYMPTOMS 0 - 2 0 0
15. HYPOCHONDRIASES 0 - 4 0 0
16. LOSS OF WEIGHT 0 - 2 1 0
1 7. INSIGHT 0 - 2 i 0 0
18. DIURNAL VARIATION 0 - 2 2 0
19. DEPERSONALISATION 0 - 4 0 0
20. PARANOID SYMPTOMS 0 - 4 I 0 0
21. OBSESSIONAL SYMPTOMS 0 - 2 0 0
22. HELPLESSNESS 0 - 4 1 1
23. HOPELESSNESS 0 - 4 1 0
24. WORTHLESSNESS 0 - 4 j 1 0
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PATIENT IDENTIFICATION: 10 SEX: F AGE: 48




SERUM PROLACTIN VALUES IN ng/ml.
L-DIHYDROXYPHENYLALANINE CHALLENGE





90 5.7 	l 4.2
TABLE XXVII
CHLORPROMAZINE CHALLENGE








PATIENT IDENTIFICATION: 11 SEX: M AGE: 23










1. DEPRESSED MOOD 0 - 4 2 0
2. FEELING OF GUILT 0 - 4 3 0
3. SUICIDE 0 - 4 1 0
4. INSOMNIA - EARLY 0 - 2 1 0
5. INSOMNIA - MIDDLE 0 - 2 0 0
6. INSOMNIA - LATE 0 - 2 0 0
7. WORK AND ACTIVITIES 0 - 4 2 0
8. RETARDATION 0 - 4 1 0
9. AGITATION 0 - 2 1 0
10. ANXIETY PSYCHIC 0 - 4 2 1
11. ANXIETY - SOMATIC 0 - 4 0 0
12. ANXIETY SYMPTOMS (G.I.T.) 0 - 2 0 0
13. SOMATIC SYMPTOMS (GEN) 0 - 2 1 0
14. GENITAL SYMPTOMS 0 - 2 0 0
15. HYPOCHONDRIASES 0 - 4 1 0
16. LOSS OF WEIGHT 0 - 2 0 0
17. INSIGHT 0 - 2 0 0
18. DIURNAL VARIATION 0 - 2 1 0
19. DEPERSONALISATION 0 - 4 0 0
20. PARANOID SYMPTOMS 0 - 4 0 0
21. OBSESSIONAL SYMPTOMS 0 - 2 1 0
22. HELPLESSNESS 0 - 4 1 0
23. HOPELESSNESS 0 - 4 2 0
24. WORTHLESSNESS 0 - 4 1 0
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PATIENT IDENTIFICATION: 11 SEX: M AGE: 23




SERUM PROLACTIN VALUES IN ng/ml.
L-DIHYDROXYPHENYLALANINE CHALLENGE
TIME IN MINUTES "ILL" VALUES "WELL" VALUES
0 11.4 1.7
20 5.7 0













1 20 9.1 14.9
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PATIENT IDENTIFICATION: 14 SEX: M AGE: 67




HAMILTON RATING SCALE FOR DEPRESSION
ITEM
SCORE ILLNESS WELL i
RANGE SCORE SCORE  
1 DEPRESSED MOOD 0 - 4 3 1
2. FEELING OF GUILT 0 - 4 1 0
3. SUICIDE 0 - 4 1 0
4. INSOMNIA - EARLY 0 - 2 1 1
1 5. INSOMNIA - MIDDLE 0 - 2 0 0
6. INSOMNIA - LATE 0 - 2 0 1
7. WORK AND ACTIVITIES 0 - 4 3 0
8. RETARDATION 0 - 4 3 0
9. AGITATION 0 - 2 0 0
10. ANXIETY PSYCHIC 0 - 4 2 0
11. ANXIETY - SOMATIC 0 - 4 1 0
12. ANXIETY SYMPTOMS (G.I.T.) 0 - 2 1 2 0
13. SOMATIC SYMPTOMS (GEN) 0 - 2 1 0 0
14. GENITAL SYMPTOMS 0 - 2 1 1 1
15. HYPOCHONDRIASES 0 - 4 1 0
16. LOSS OF WEIGHT 0 - 2 1 0
17. INSIGHT 0 - 2 1 1
18. DIURNAL VARIATION 0 - 2 1 0
19. DEPERSONALISATION 0 - 4 2 0
20. PARANOID SYMPTOMS 0 - 4 1 0
21. OBSESSIONAL SYMPTOMS 0 - 2 0 0
22. HELPLESSNESS 0 - 4 2 0
23. HOPELESSNESS 0 - 4 2 1
24. WORTHLESSNESS 0 - 4 2 1 0
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PATIENT IDENTIFICATION: 14 SEX: M AGE: 67




SERUM PROLACTIN VALUES IN ng/ml.
L-DIHYDROXYPHENYLALANINE CHALLENGE
TIME IN MINUTES "ILL" VALUES "WELL" VALUES   
0 0 5.1
1 20 0 1.5





TIME IN MINUTES "ILL" VALUES "WELL" VALUES
0 0 7.7






PATIENT IDENTIFICATION: 15 SEX: F AGE: 58












1. DEPRESSED MOOD 0 - 4 3 0
2. FEELING OF GUILT 0 - 4 3 0
3. SUICIDE 0 - 4 3 0
4. INSOMNIA - EARLY 0 - 2 0 1
5. INSOMNIA - MIDDLE 0 - 2 2 1
6. INSOMNIA - LATE 0 - 2 2 0
7. WORK AND ACTIVITIES 0 - 4 . 3 0
8. RETARDATION 0 - 4 3 0
9. AGITATION 0 - 2 1 0
10. ANXIETY PSYCHIC 0 - 4 3 1
11. ANXIETY - SOMATIC 0 - 4 0 0
12. ANXIETY SYMPTOMS (G.I.T.) 0 - 2 0 i 1
13. SOMATIC SYMPTOMS (GEN) 0 - 2 1 I 1
14. GENITAL SYMPTOMS 0 - 2 2 0
15. HYPOCHONDRIASES 0 - 4 0 0
16. LOSS OF WEIGHT 0 - 2 i
1
 1 0
17. INSIGHT 0 - 2 i 1 0
11 8. DIURNAL VARIATION 0 - 2 0 0
19. DEPERSONALISATION 0 - 4 2 0
20. PARANOID SYMPTOMS 0 - 4 2 0
21. OBSESSIONAL SYMPTOMS 0 - 2 I 1 0
22. HELPLESSNESS 0 - 4 1
1
 3 0
23. HOPELESSNESS 0 - 4 4 0
124. WORTHLESSNESS 0 - 4 3 10 1
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PATIENT IDENTIFICATION: 15 SEX: F AGE: 58




SERUM PROLACTIN VALUES IN ng/ml.
L-DIHYDROXYPHENYLALANINE CHALLENGE
TIME IN MINUTES "ILL" VALUES "WELL" VALUES




90 1 2.0 41.5
TABLE XXXVI
CHLORPROMAZ INE CHALLENGE






1 20 16.0 14.3
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PATIENT IDENTIFICATION: 16 SEX: M AGE: 55











SCORE    
1. DEPRESSED MOOD 0 - 4 3 1
2. FEELING OF GUILT 0 - 4 0 0
3. SUICIDE 0 - 4 1 0
4. INSOMNIA - EARLY 0 - 2 0 0
5. INSOMNIA - MIDDLE 0 - 2 1 0
6. INSOMNIA - LATE 0 - 2 1 0
7. WORK AND ACTIVITIES 0 - 2 1
8. RETARDATION 0 - 4 1 0
9. AGITATION 0 - 2 0 0
10. ANXIETY PHYSIC 0 - 4 2 0
11. ANXIETY - SOMATIC 0 - 4 0 0
12. ANXIETY SYMPTOMS (G.I.T.) 0 - 2 0 0
13. SOMATIC SYMPTOMS (GEN) 0 - 2 0 0
114. GENITAL SYMPTOMS 0 - 2 1 1 1
15. HYPOCHONDRIASES 0 - 4
1
' 2 2
16. LOSS OF WEIGHT 0 - 2 1 0
17. INSIGHT 0 - 2 0 0
18. DIURNAL VARIATION 0 - 2 1 1
19. DEPERSONALISATION 0 - 4 0 0
20. PARANOID SYMPTOMS 0 - 4 0 0
21. OBSESSIONAL SYMPTOMS 0 - 2 0 0
22. HELPLESSNESS 0 - 4 1 0
23. HOPELESSNESS 0 - 4 2 1
24. WORTHLESSNESS 0 - 4 2 1
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PATIENT IDENTIFICATION: 16 SEX: M AGE: 55




SERUM PROLACTIN VALUES IN ng/ml.
L-DIHYDROXYPHENYLALANINE CHALLENGE















1 20 9.8 1 2.8 1
I
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PATIENT IDENTIFICATION: 17 SEX: F AGE: 52









1. DEPRESSED MOOD 0 - 4 3 0
2. FEELING OF GUILT 0 - 4 2 1
3. SUICIDE 0 - 4 1 0
4. INSOMNIA - EARLY 0 - 2 0 0
5. INSOMNIA - MIDDLE 0 - 2 0 0
6. INSOMNIA - LATE 0 - 2 2 1
7. WORK AND ACTIVITIES 0 - 4 3 1
8. RETARDATION 0 - 4 2 0
9. AGITATION 0 - 2 1 0
10. ANXIETY PSYCHIC 0 - 4 3 2
11. ANXIETY - SOMATIC 0 - 4 1 0
12. ANXIETY SYMPTOMS (G.I.T.) 0 - 2 0 0 I
13. SOMATIC SYMPTOMS (GEN) 0 - 2 2 1
14. GENITAL SYMPTOMS 0 - 2 i 1 1
15. HYPOCHONDRIASES 0 - 4 I 2 1
16. LOSS OF WEIGHT 0 - 2 2 0
17. INSIGHT 0 - 2 1 0
18. DIURNAL VARIATION 0 - 2 0 0 I
19. DEPERSONALISATION 0 - 4 0 0
20. PARANOID SYMPTOMS 0 - 4 2 0
21. OBSESSIONAL SYMPTOMS 0 - 2 1 0
22. HELPLESSNESS 0 - 4 2 0
23. HOPELESSNESS 0 - 4 2 0
24. WORTHLESSNESS 0 - 4 2 1
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PATIENT IDENTIFICATION: 17 SEX: F AGE: 52




SERUM PROLACTIN VALUES IN ng/ml.
L-DIHYDROXYPHENYLALANINE CHALLENGE










TIME IN MINUTES "ILL" VALUES "WELL" VALUES
0 6.3 1 2.5
20 10.7 10.9





PATIENT IDENTIFICATION: 18 SEX: M AGE: 61












1. DEPRESSED MOOD 0 - 4 3 1
2. FEELING OF GUILT 0 - 4 0 0
3. SUICIDE 0 - 4 1 1
4. INSOMNIA - EARLY 0 - 2 2 0
5. INSOMNIA - MIDDLE 0 - 2 0 0
6. INSOMNIA - LATE 0 - 2 1 0
7. WORK AND ACTIVITIES 0 - 4 2 1
8. RETARDATION 0 - 4 2 1
9. AGITATION 0 - 2 1 1
10. ANXIETY PSYCHIC 0 - 4 3 3
11. ANXIETY - SOMATIC 0 - 4 1 0
12. ANXIETY SYMPTOMS (G.I.T.) 0 - 2 1 0
13. SOMATIC SYMPTOMS (GEN) 0 - 2 1 0 
14. GENITAL SYMPTOMS 0 - 2 2 2
15. HYPOCHONDRIASES 0 - 4 2 2
16. LOSS OF WEIGHT 0 - 2 1 0
17. INSIGHT 0 - 2 0 0
18. DIURNAL VARIATION 0 - 2 1 0
19. DEPERSONALISATION 0 - 4 0 0
20. PARANOID SYMPTOMS 0 - 4 i 0 0
21. OBSESSIONAL SYMPTOMS 0 - 2 0 0
22. HELPLESSNESS 0 - 4 2 0
23. HOPELESSNESS 0 - 4 2 2
24. WORTHLESSNESS 0 - 4 1 1
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PATIENT IDENTIFICATION: 18 SEX: M AGE: 61




SERUM PROLACTIN VALUES IN ng/ml.
L-DIHYDROXYPHENYLALANINE CHALLENGES
















PATIENT IDENTIFICATION: 19 SEX: F AGE: 53












1. DEPRESSED MOOD 0 - 4 4 2
2. FEELING OF GUILT 0 - 4 0 0
3 . SUICIDE 0 - 4 0 0
4 . INSOMNIA - EARLY 0 - 2 2 2
5 . INSOMNIA - MIDDLE 0 - 2 2 1
6 . INSOMNIA - LATE 0 - 2 2 2
7. WORK AND ACTIVITIES 0 - 4 4 2
8. RETARDATION 0 - 4 4 2
9. AGITATION 0 - 2 0 0
10. ANXIETY PSYCHIC 0 - 4 0 0
11. ANXIETY - SOMATIC 0 - 4 0 0
12. ANXIETY SYMPTOMS (G.I.T.) 0 - 2 0 0
13. SOMATIC SYMPTOMS (GEN) 0 - 2 1 0
14. GENITAL SYMPTOMS 0 - 2 0 0
15. HYPOCHONDRIASES 0 - 4 0 0
16. LOSS OF WEIGHT 0 - 2 2 1
17. INSIGHT 0 - 2 2 1
h
I
8. DIURNAL VARIATION 0 - 2 0 0
119. DEPERSONALISATION 0 - 4 2 0
1
20. PARANOID SYMPTOMS 0 - 4 0 0
I
21. OBSESSIONAL SYMPTOMS 0 - 2 0 0
i
1 22. HELPLESSNESS 0 - 4 4 3
123. HOPELESSNESS 0 - 4 3 2
124. WORTHLESSNESS 0 - 4 3 2
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PATIENT IDENTIFICATION: 19 SEX: F AGE: 53




SERUM PROLACTIN VALUES IN ng/ml.
L-DIHYDROXYPHENYLALANINE CHALLENGE










TIME IN MINUTES "ILL" VALUES
!
"WELL" VALUES 1
0 1 7.6 2.6
20 10.7 6.0
40 12.6 8.8
60 14.6 1 3.3
90 17.1 19.2
120 1 8.4 28.7
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PATIENT IDENTIFICATION: 20 SEX: F AGE: 69












1. DEPRESSED MOOD 0 - 4 2 1
2. FEELING OF GUILT 0 - 4 1 0
3. SUICIDE 0 - 4 1 0
1 4. INSOMNIA - EARLY 0 - 2 2 1
5. INSOMNIA - MIDDLE 0 - 2 0 0
6. INSOMNIA - LATE 0 - 2 1 0
7. WORK AND ACTIVITIES 0 - 4 2 1
8. RETARDATION 0 - 4 1 0
9. AGITATION 0 - 2 1 1
10. ANXIETY PHYSIC 0 - 4 3 2
11. ANXIETY - SOMATIC 0 - 4 1 0
12. ANXIETY SYMPTOMS (G.I.T.) 0 - 2 0 0
13. SOMATIC SYMPTOMS (GEN) 0 - 2 1 0
14. GENITAL SYMPTOMS 0 - 2 1 0
15. HYPOCHONDRIASES 0 - 4 0 0
16. LOSS OF WEIGHT 0 - 2 2 1
17. INSIGHT 0 - 2 1 0
18. DIURNAL VARIATION 0 - 2 1 1
19. DEPERSONALISATION 0 - 4 0 0
20. PARANOID SYMPTOMS 0 - 4 2 0
21. OBSESSIONAL SYMPTOMS 0 - 2 I 1 1
22. HELPLESSNESS 0 - 4 2 1
23. HOPELESSNESS 0 - 4 2 1
24. WORTHLESSNESS 0 - 4 1 1
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PATIENT IDENTIFICATION: 20 SEX: F AGE: 69




SERUM PROLACTIN VALUES IN ng/ml.
L-DIHYDROXYPHENYLALANINE CHALLENGE








TIME IN MINUTES I "ILL" VALUES "WELL" VALUES
10 1 3.3 3.1
20 2.2 3.0
40 5.9 6.6




PATIENT IDENTIFICATION: 21 SEX: F AGE: 56












1. DEPRESSED MOOD 0 - 4 3 0
2. FEELING OF GUILT 0 - 4 3 1
3. SUICIDE 0 - 4 2 0
4. INSOMNIA - EARLY 0 - 2 2 0
5. INSOMNIA - MIDDLE 0 - 2 1 0
6. INSOMNIA - LATE 0 - 2 1 0
7 . WORK AND ACTIVITIES 0 - 4 2 0
8 . RETARDATION 0 - 4 2 0
9. AGITATION 0 - 2 1 0
10. ANXIETY PSYCHIC 0 - 4 3 1
11. ANXIETY - SOMATIC 0 - 4 1 1
12. ANXIETY SYMPTOMS (G.I.T.) 0 - 2 1 0
13. SOMATIC SYMPTOMS (GEN) 0 - 2 0 0
14. GENITAL SYMPTOMS 0 - 2 i 2 1
15. HYPOCHONDRIASES 0 - 4 1 2 1
16. LOSS OF WEIGHT 0 - 2 1 0
17. INSIGHT 0 - 2 i 2 0
18. DIURNAL VARIATION 0 - 2 2 0
19. DEPERSONALISATION 0 - 4 0 0
20. PARANOID SYMPTOMS 0 - 4 1 0
21. OBSESSIONAL SYMPTOMS 0 - 2 2 2
22. HELPLESSNESS 0 - 4 2 0
23. HOPELESSNESS 0 - 4 2 1
24. WORTHLESSNESS 0 - 4 2 0
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PATIENT IDENTIFICATION: 21 SEX: F AGE: 56




SERUM PROLACTIN VALUES IN ng/ml.
L-DIHYDROXYPHENYLALANINE CHALLENGE








TIME IN MINUTES "ILL" VALUES
1
i 	"WELL" VALUES 1
0 6.7 17.4
20 6.1 13.5
40 8.0 1 	21.6





PATIENT IDENTIFICATION: 23 SEX: F AGE: 60











1. DEPRESSED MOOD 0 - 4 2 1
2. FEELING OF GUILT 0 - 4 0 0
3. SUICIDE 0 - 4 1 0
4. INSOMNIA - EARLY 0 - 2 1 1
5. INSOMNIA - MIDDLE 0 - 2 1 0
6. INSOMNIA - LATE 0 - 2 1 1
7. WORK AND ACTIVITIES 0 - 4 2 1
8. RETARDATION 0 - 4 0 0
9. AGITATION 0 - 2 1 0
10. ANXIETY PSYCHIC 0 - 4 2 1
11. ANXIETY - SOMATIC 0 - 4 2 1
12. ANXIETY SYMPTOMS (G.I.T.) 0 - 2 1 0
13. SOMATIC SYMPTOMS (GEN) 0 - 2 0 0
14. GENITAL SYMPTOMS 0 - 2 1 0
15. HYPOCHONDRIASES 0 - 4 0 0
16. LOSS OF WEIGHT 0 - 2 1 1
17. INSIGHT 0 - 2 1 0
18. DIURNAL VARIATION 0 - 2 0 0
19. DEPERSONALISATION 0 - 4 0 0
20. PARANOID SYMPTOMS 0 - 4 2 0
21. OBSESSIONAL SYMPTOMS 0 - 2 0 0
22. HELPLESSNESS 0 - 4 0 0
23. HOPELESSNESS 0 - 4 1 1
24. WORTHLESSNESS 0 - 4 1 0
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PATIENT IDENTIFICATION: 22 SEX: F AGE: 60




SERUM PROLACTIN VALUES IN ng/ml.
L-DIHYDROXYPHENYLALANINE CHALLENGE













90 16.4 i 16.5
120 17.7 14.2
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PATIENT IDENTIFICATION: 23 SEX: F AGE: 70









1. DEPRESSED MOOD 0 - 4
1
3 1
2. FEELING OF GUILT 0 - 4 1 0
3. SUICIDE 0 - 4 2 0
4. INSOMNIA - EARLY 0 - 2 1 1
5. INSOMNIA - MIDDLE 0 - 2 1 0
6. INSOMNIA - LATE 0 - 2 1 0
7. WORK AND ACTIVITIES 0 - 4 3 1 i
8. RETARDATION 0 - 4 3 1
9. AGITATION 0 - 2 0 0
10. ANXIETY PSYCHIC 0 - 4 1 1
11. ANXIETY - SOMATIC 0 - 4 0 0
12. ANXIETY SYMPTOMS (G.I.T.) 0 - 2 1 1
13. SOMATIC SYMPTOMS (GEN) 0 - 2 1 0
14. GENITAL SYMPTOMS 0 - 2 0 0
15. HYPOCHONDRIASES 0 - 4 1 0
16. LOSS OF WEIGHT 0 - 2 1 2
17. INSIGHT 0 - 2 1 0
18. DIURNAL VARIATION 0 - 2 0 0
19. DEPERSONALISATION 0 - 4 0 0
20. PARANOID SYMPTOMS 0 - 4 2 0
21. OBSESSIONAL SYMPTOMS 0 - 2 0 0
22. HELPLESSNESS 0 - 4 3 1
23. HOPELESSNESS 0 - 4 3 1
24. WORTHLESSNESS 0 - 4 2 1 0
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PATIENT IDENTIFICATION: 23 SEX: F AGE: 70




SERUM PROLACTIN VALUES IN ng/ml.
L-DIHYDROXYPHENYLALANINE CHALLENGE
















PATIENT IDENTIFICATION: 25 SEX: F AGE: 65












1. DEPRESSED MOOD 0 - 4 3 1
2. FEELING OF GUILT 0 - 4 3 1
3. SUICIDE 0 - 4 2 0
4. INSOMNIA - EARLY 0 - 2 1 0
5. INSOMNIA - MIDDLE 0 - 2 0 0
6. INSOMNIA - LATE 0 - 2 1 0
7. WORK AND ACTIVITIES 0 - 4 2 1
8. RETARDATION 0 - 4 j 0 0
9. AGITATION 0 - 2 I 2 0
10. ANXIETY PSYCHIC 0 - 4 2 1
11. ANXIETY - SOMATIC 0 - 4 2 1
12. ANXIETY SYMPTOMS (G.I.T.) 0 - 2 1 1
13. SOMATIC SYMPTOMS (GEN) 0 - 2 1 1
14. GENITAL SYMPTOMS 0 - 2 1 0
15. HYPOCHONDRIASES 0 - 4 3 2
16. LOSS OF WEIGHT 0 - 2 0 0
17. INSIGHT 0 - 2 2 0
18. DIURNAL VARIATION 0 - 2 0 0
19. DEPERSONALISATION 0 - 4 0 0
20. PARANOID SYMPTOMS 0 - 4 3 0
21. OBSESSIONAL SYMPTOMS 0 - 2 1 1
22. HELPLESSNESS 0 - 4 1 0
23. HOPELESSNESS 0 - 4 1 0
24. WORTHLESSNESS 0 - 4 3 1
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PATIENT IDENTIFICATION: 25 SEX: F AGE: 65




SERUM PROLACTIN VALUES IN ng/ml.
L-DIHYDROXYPHENYLALANINE CHALLENGE








TIME IN MINUTES "ILL" VALUES "WELL" VALUES
0 5.7 7.5
20 5.9 6.3
40 1 0.0 11.1
60 1 5.7 17.0
90 20.3 21.8
120 1 7.5 21.0
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PATIENT IDENTIFICATION: 2 SEX: F AGE: 19










1. MOTOR ACTIVITY 1 - 5 4 1
2. PRESSURE OF SPEECH 1 - 5 3 2
3. FLIGHT OF IDEAS 1 - 5 2 1
4. NOISINESS 1 - 5 2 1
5. AGGRESSIVENESS 1 - 5 2 1
6. ORIENTATION 1 - 3 1 1
7. ELEVATED MOOD 1 - 5 3 1
8. GLOBAL RATING OF MANIA 1 - 5 3 1
TOTAL 20 9
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PATIENT IDENTIFICATION: 2 SEX: F AGE: 19




SERUM PROLACTIN VALUES IN ng/ml.
L-DIHYDROXYPHENYLALANINE CHALLENGE
















PATIENT IDENTIFICATION: 9 SEX: F AGE: 54










1. MOTOR ACTIVITY 1 - 5 2 1
2. PRESSURE OF SPEECH 1 - 5 2 1
3. FLIGHT OF IDEAS 1 - 5 1 1
4. NOISINESS 1 - 5 2 1
5. AGGRESSIVENESS 1 - 5 2 1
6. ORIENTATION 1 - 3 1 1
7. ELEVATED MOOD 1 - 5 2 1
8. GLOBAL RATING OF MANIA 1 - 5 2 1
TOTAL 14 8
121
PATIENT IDENTIFICATION: 9 SEX: F AGE: 54




SERUM PROLACTIN VALUES IN ng/ml.
L-DIHYDROXYPHENYLALANINE CHALLENGE
TIME IN MINUTES "ILL" VALUES "WELL" VALUES
0 25.8 8.7












120 1 20.5 21.6
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PATIENT IDENTIFICATION: 13 SEX: F AGE: 32




PETTERSEN RATING SCALE FOR MANIA
ITEM SCORE ILLNESS WELL
RANGE SCORE SCORE
1. MOTOR ACTIVITY 1 - 5 , 3 2
2. PRESSURE OF SPEECH 1 - 5 2 1
3. FLIGHT OF IDEAS 1 - 5 2 1
4. NOISINESS 1 - 5 1 1
5. AGGRESSIVENESS 1 - 5 3 1
6. ORIENTATION 1 - 3 1 1
7. ELEVATED MOOD 1 - 5 2 1
8. GLOBAL RATING OF MANIA 1 - 5 3 1
TOTAL 17 9
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PATIENT IDENTIFICATION: 13 SEX: F AGE: 32




SERUM PROLACTIN VALUES IN rig/ml.
L-DIHYDROXYPHENYLALANINE CHALLENGE








TIME IN MINUTES "ILL" VALUES "WELL" VALUES
0 8.2 6.7
20 1 0.6 8.8
40 16.3 13.1
60 27.4 16.9
90 1 7.2 19.9
1 20 23.0
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PATIENT IDENTIFICATION: 14 SEX: M AGE: 62











1. MOTOR ACTIVITY 1 - 5 2 1
2. PRESSURE OF SPEECH 1 - 5 3 2
3. FLIGHT OF IDEAS 1 - 5 2 1
4. NOISINESS 1 - 5 2 1
5. AGGRESSIVENESS 1 - 5 2 1
6. ORIENTATION 1 - 3 1 1
7. ELEVATED MOOD 1 - 5 3 1
8. GLOBAL RATING OF MANIA 1 - 5 3 1
TOTAL 18 9
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PATIENT IDENTIFICATION: 14 SEX: M AGE: 62




SERUM PROLACTIN VALUES IN ng/ml
L-DIHYDROXYPHENYLALANINE CHALLENGE




60 3.8 i 4.1
90 5.0 0.9
TABLE LXXV
CHLORPROMAZINE CHALLENGE        
TIME IN MINUTES "ILL" VALUES "WELL" VALUES    
0 8.8 8.0
20 1 0.2 6.9
40 9.1 1.2
60 11.3 1 0.5
90 1 4.9 16.8
1 20 1 9.9 25.1
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PATIENT IDENTIFICATION: 19 SEX: F AGE: 53











1. MOTOR ACTIVITY 1 - 5 2 1
2. PRESSURE OF SPEECH 1 - 5 2 1
3. FLIGHT OF IDEAS 1 - 5 1 1
4. NOISINESS 1 - 5 2 1
5. AGGRESSIVENESS 1 - 5 1 1
6. ORIENTATION 1 - 3 1 1
7. ELEVATED MOOD 1 - 5 2 1
8. GLOBAL RATING OF MANIA 1 - 5 2 1
TOTAL 13 8
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PATIENT IDENTIFICATION: 19 SEX: F AGE: 53




SERUM PROLACTIN VALUES IN ng/ml
L-DIHYDROXYPHENYLALANINE CHALLENGE
















PATIENT IDENTIFICATION: 24 SEX: M AGE: 79










1. MOTOR ACTIVITY 1 - 5 2 1
2. PRESSURE OF SPEECH 1 - 5 3 2
3. FLIGHT OF IDEAS 1 - 5 3 1
4. NOISINESS 1 - 5 3 1
5. AGGRESSIVENESS 1 - 5 2 2
6. ORIENTATION 1 - 3 1 1
7. ELEVATED MOOD 1 - 5 3 1
8. GLOBAL RATING OF MANIA 1 - 5 3 2
TOTAL 20 11
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PATIENT IDENTIFICATION: 24 SEX: M AGE: 79




SERUM PROLACTIN VALUES IN ng/ml
L-DIHYDROXYPHENYLALANINE CHALLENGE
















PATIENT IDENTIFICATION: 2 6 SEX: F AGE: 21











1. MOTOR ACTIVITY 1 - 5 3 1
2. PRESSURE OF SPEECH 1 - 5 3 1
3. FLIGHT OF IDEAS 1 - 5 2 1
4. NOISINESS 1 - 5 2 1
5. AGGRESSIVENESS 1 - 5 3 1
6. ORIENTATION 1 - 3 1 1
7. ELEVATED MOOD 1 - 5 3 1
8. GLOBAL RATING OF MANIA 1 - 5 3 1
TOTAL 20 8
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PATIENT IDENTIFICATION: 26 SEX: F AGE: 21




SERUM PROLACTIN VALUES IN ng/ml
L-DIHYDROXYPHENYLALANINE CHALLENGE
TIME IN MINUTES "ILL" VALUES "WELL" VALUES
0 38.8 2.0
20 1 5.2 0.7
40 13.8 0.3












PATIENT IDENTIFICATION: 27 SEX: M AGE: 24











1. MOTOR ACTIVITY 1 - 5 2 1
2. PRESSURE OF SPEECH 1 - 5 2 1
3. FLIGHT OF IDEAS 1 - 5 2 1
4. NOISINESS 1 - 5 2 1
5. AGGRESSIVENESS 1 - 5 1 1
6. ORIENTATION 1 - 3 1 1
7. ELEVATED MOOD 1 - 5 2 1
8. GLOBAL RATING OF MANIA 1 - 5 2 1
TOTAL 14 8
133
PATIENT IDENTIFICATION: 27 SEX: M AGE: 24




SERUM PROLACTIN VALUES IN ng/ml.
L-DIHYDROXYPHENYLALANINE CHALLENGE

















A considerable amount of variability in the Raw Data is evi-
dent. Reference to Table LXXXVIII (Summary of Statistics),
and in particular columns "Standard Deviation" and "Coeffi-
cient of Variation", is indicative of this relatively high
variability of the data at hand.
While on occasions experimental error may account for some of
the variability, the accuracy of the assay technique, as indi-
cated previously, is high. Due to the variability of the data,
it was decided to apply non-parametric statistical procedures
to the data, in an attempt to see whether or not there was a
significant movement of prolactin values from the illness
phases to the recovery phases.
The Wilcoxon Matched Pairs Signed Ranks Test was applied,
not only to see the direction of movement but also to assess
the relative magnitude of the shifts. The direction of move-
ment is given by the sign of ill minus recovered scores. The
significance of the magnitude of the ill minus recovered
scores is given by the p = value.
Individual analyses were carried out for each of the values
of prolactin at 0, 20, 40, 60, 90 minutes and at 120 minutes
for the chlorpromazine challenge. Analyses were also carried
out on the sum of the prolactin levels for each challenge
procedure including the baseline values, i.e. the sum of
values from time 0 to 90 minutes for L-dihydroxvphenylalanine,
and to 120 minutes for chlorpromazine.
The results of the analyses of each of the challenge proce-
dures (1) depressives/L-dihydroxyphenylalarline, (2) depres-
sives/chlorpromazine, (3) manic/L-dihydroxyphenylalanine,
(4) manic-chlorpromazine are presented in Tables LXXXIX -
XCII with appropriate comments.
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Summary of Statistics
TABLE LXXXVI I I
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5.2.1 Depressives : L-dihydroxyphenylalanine Challenge 
Data Analyses 
Table LXXXIX gives the results of the statistical analysis
of prolactin values resulting from investigations during the
depressive phase and on recovery following L-dihydroxyphenyl-
alanine challenge, including baseline values. It can be seen
that all shifts were in a negative direction (sign of ill
minus recovered), that is the values of prolactin levels
moved from lower to higher levels on recovery. These changes
in values were not statistically significant. Value C (being
at time 20 minutes) shows the most significant change
(p = 0,0582). An analysis of the sum of the individual values




























Sum of times - 0,1842
5.2.2 Depressives : Chlorpromazine Challenge Data Analysis 
Table XC gives the results of the statistical analysis
carried out on prolactin values resulting from investigation
during the depressive phase and on recovery with chlorpro-
mazine challenge. Again both the individual values at the
different times and the sum of the individual values were
subjected to analysis.
It can be seen that a number of significant results were
obtained. A significant change was found on the sum of the
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individual values p = 0,0058, as was the case with the base-
line measures B (p = 0,0096) and the measures at times,
D (p = 0,0157), E (p = 0,0038), F (p = 0,0065), and G













zine E-60 - 0,0028
F-90 - 0,0065
G-120 - 0,0168
Sum of times - 0,0058
Not only were the changes significant but all were in the
direction from lower values when depressed to higher values
when recovered. There were, therefore, significant changes on
the chlorpromazine challenge test times 0, 40, 60, 90 minutes
and the sum of the individual values. It would appear, how-
ever, from this data that the challenge with chlorpromazine
is probably unnecessary in that the baseline values would be
a good index of the disturbance of prolactin regulation in
the depressed phase, baseline change being highly significant
(p = 0,0096). Very significant results here indicate that the
prolactin levels are lower in the depressed phase and increase
upon recovery from depression.
5.2.3 Manics : L-dihydroxyphenylalanine Challenge Data
Analysis 
Table XCI gives the results of the statistical analysis of
prolactin values resulting from investigation during the manic
phases and on recovery with the L-dihydroxyphenylalanine chal-
138
lenge procedure.
As occurred previously individual value changes at the
various times and the changes in the sum of the values in
the manic and recovery phases were analysed.
There was a significant change in the sum of the individual
values from the manic phase to the recovery phase (p =
0,0050) the direction of these changes was from higher
values to lower values upon recovery (ill minus recovery
being positive).
Baseline levels B (time 0 minutes ) also changed in the same
direction and attained significance at the 0,0521 level.
Changes in values for prolactin at times C (20 minutes) and
F (90 minutes) attained significance at the 0,0500 level.
While other value shifts did not reach significance all the
signs were positive indicating that the changes were in the

























Sum of times + 0,0500
5.2.4. Manics : Chlorpromazine Challenge Data Analyses 
Table XCIlgives the results of the statistical analysis on
prolactin values resulting from investigation during the
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manic phase and on recovery with the chlorpromazine challenge
procedures.
The shift in values of prolactin were positive at times 0,
20, 40, 60, 90 and 120 minutes. This indicated a decrease
from higher levels to lower levels on recovery. The change
of values obtained at times, C (20 minutes), D (40 minutes)
and E (60 minutes) were significant at 0,0173, 0,028 and
0,0173 respectively. The change in value for the sum of the
values at the different times failed to attain significance
= 0,0679). The direction of change was again positive











Manic Chlorproma- D-40 + 0,0280
zine E-60 + 0,0173
F-90 + 0,8658
G-120 + 0,2489
Sum of times + 0,0679
5.2.5 Motor Activity and Prolactin
Of particular interest is the relationship between motor
activity and changes in prolactin from ill to recovered. The
depressive scale item "retardation" was considered to be
indicative of "impaired" motor function. This item is fairly
heavily weighted having a five point rating. In the manic
group the level of motor activity is given on the "motor
activity" scale; this also having a five point rating.
The results of the analyses of variance are not given as
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problems were experienced in handling the data. When looking
at the various ratings for both retardation and motor activi-
ty the number of subjects in the various groups of retarda-
tion/motor activity proved to be small. The largest group
obtained for any rating was in the "variable one" group
(depressed : L-dihydroxyphenylalanine) with ratings of three
on retardation (n = 5). No really useful information was
derived from these analyses. An increase in the number of
subjects is very desirable in order to obtain significant





6.1.1 Depressive Subjects' Data Analyses 
Discrepancies in the results of the statistical analyses as
seen in Tables LXXXIX and XC require consideration:-
The L-dihydroxyphenylalanine challenge was the first chal-
lenge to be done on each subject. It is possible that the
novelty of the situation, as this was the first contact with
the research procedure, increased the stress in these subjects.
It is also possible that the stress effect was not short lived
but was relatively sustained throughout the 100 minute period
of investigation.
The depressed subjects, as these were on the first encounter,
are more likely to respond with excessive stress than recover-
ed subjects, particularly as the recovered groups were no
longer naive.
Both these effects could raise the levels of prolactin. Such
a possible rise in the depressed period could reduce the mag-
nitude of the change in prolactin values, thus leading to a
reduction of the significance of the changes. One may have
expected the baseline (time 0) values to have been substan-
tially affected. The changes in values are in the same direc-
tion (sign of ill minus recovered is negative) i.e. low
values in the depressed phase to higher values on recovery.
In view of the fact that the L-dihydroxyphenylalanine chal-
lenge was generally carried out on the day before (24 hours)
the chlorpromazine challenge, the emergence of positive re-
sults on the chlorpromazine challenge may have been influenced
by some "priming effect" by L-dihydroxyphenvlalanine. It is,
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however, to be noted that the same procedure was carried out
with the recovery challenge, making the effects in all pro-
bability, comparable. It is still possible that in the
condition of depressed or recovered there may be a greater
susceptibility to "priming". In the unlikely event of such
an effect it is improbable that the validity of the test
would be affected.
6.1.2 Manic Subjects' Data Analyses 
The discrepancies here are not so problematic. On the whole
significant results were obtained from both the L-dihydroxy-
phenylalanine and the chlorpromazine challenges. Unfortunate-
ly the baseline values (time 0 minutes) for the chlorpromazine
challenge failed to reach significance (p = 0,1235), nor did
the sum of the individual values show a significant shift
(p = 0,0679).
A number of factors operated here which probably reduced the
significance of the changes in values. The sample of subjects
(n = 8) is rather small. In view of the clinical difficulty
of handling these patients while observing a washout period,
only hypomanic and moderately manic patients can be opera-
tionally managed. A further factor was that older patients
were included (one of 79 years) who should probably not have
been admitted to the study. It is evident from looking at the
raw data that these patients did not conform to the pattern
of the younger patients. This may well be a product of the
ageing process. Further studies are required to clarify this
matter. The difficulty of obtaining suitable hypomanic/mod-
erately manic patients lead to the inclusion of these elderly
subjects who were easier to handle. This may be a significant
selecting factor as age may well be associated with some
muting of the amplitude of the disturbance of prolactin activ-
ity.
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6.1.3 Significance of Results 
This study has produced substantial evidence that dopamine
function may be disturbed in primary affective disorders.
It may be argued that there is a non-specific disturbance in
prolactin function and not primarily a dopamine dysfunction.
Such a non-specific disturbance being possibly stress related,
should lead to increased levels of prolactin in the depressive
phase, making this explanation unlikely.
A further possibility is that other transmitter regulating
factors may be disturbed, explaining the apparent inversion
of expected or hypothesised prolactin levels in depression
and mania. Serotonergic stimulation of prolactin is via the
prolactin releasing factor. Reduced serotonergic function,
for instance, would lead to reduced levels of prolactin - in
keeping with the traditional indoleamine theory of depression.
This may indeed be so, but there is reason to believe that
over and above any such influence dopamine is also subject to
disturbance.
Another non-specific disturbance, at pituitary level, can be
postulated, this could explain the depressive effects as being
due to a generally "sluggish" pituitary. Manic effects would
be more difficult to explain on this basis, as would be the
disturbance seen in the pituitary adreno-cortical axis.
The non-specific effect of "motor behaviour" should be
approached with extreme caution. What constitutes a non-speci-
fic effect and what is indeed a highly specific effect is of
fundamental importance, as dopamine is probably the primary
transmitter in driving and executing motor function!
The expectation that a hyperdopaminergic state occurs in mania
and a correspondingly hypodopaminergic state occurs in de-
pression, would not readily explain the reverse effects seen
in the prolactin values in this study. The expectation would
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be to find reduced levels of prolactin in mania, increased
dopamine function giving rise to increased inhibition of
prolactin. Depression conversely may be expected to be
associated with raised prolactin levels due to reduced in-
hibition by dopamine.
The apparent difficulty in relating the prolactin changes to
dopamine function may be purely due to the fact that the
relationships within the dopamine systems are disturbed. An
apparent ba3ance exists between the inhibitory and the ex-
citatory systems (van Rooyen 1980). The implication is of a
reciprocal relationship with both irthibitory and excitatory
functions available i the emergence of a reverse pattern could
be expected.
The dysfunction of inhibition may be an expression of in-
creased excitatory (D 2 ) system function in mania, excitatory
ascendency with a relative reduction of inhibition. In de-
pression the impaired excitation may then be associated with
a relative increase of inhibition, hence the lower levels of
prolactin.
The mechanisms of such a change is unclear, whether the D
2
system drives neurones which inhibit the tubero-infundibular
neurones remains to be elucidated; possibly neurones of the




dopamine receptors on adenylate cyclase has been referred to
previously (Stoof and Kebabian, 1981). Conversely disturbance
within the inhibiting systems may give rise to increased ex-
citatory function due to lack of modulation by the D
1 
system
in mania. The reverse would hold for depression.
Some disturbance of the dopamine receptors (D 4 ) is suggested
by supersensitivity patterns which certainly indicate modi-
fied receptors. These changes are more likely to be secon-
dary than primary.
Examination of the raw data on pages 119,121, 123, 131 and
133 suggests that not only is there a reduced inhibitory
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function in mania, but that the dopamine receptors may be
supersensitive. As stated before, the data may be distorted
by the very elderly patients (79 years), while many of the
other patients show a clear trend to a supersensitivity
pattern. The raw prolactin data of patients, identification
numbers 2, 9 and 26 in particular, demonstrate high receptor
sensitivity (see pages 119, 121 and 131 respectively). Exam-
ination of the raw data on pages 91 and 121 show the depres-
sive and manic data of the same patient. This data shows
gross shifts in prolactin levels from depressed to manic
state. Again the receptor supersensitivity pattern is evi-
dent (page 121). The problem of the nature of the dopamine
receptors on the pituitary mammotrophs is most important.
They appear to be inhibitory either non-adenylate cyclase de-
pendent, or negatively regulating adenylate cyclase. An
additional factor is the high level of sensitivity of these
receptors (see discussion on dopamine receptors). They may
not be identical to those occurring elsewhere despite signifi-
cant similarities to the D..) receptors. It may be difficult to
extrapolate from data derived from their functional changes.
Additional factors in discussing the results of this investi-
gation need to be emphasised. While the D 4 dopamine receptors
appear to be important on the mammotrophs, D 1 receptors have
also been demonstrated in the adenohypothesis (van Rooyen
1980). Reduced dopamine inhibition (D 1 ) could lead to re-
lease of dopamine excitation (D 2 ) due to their oppositional
relationship (Stodf and Kebabian, 1981). Further know-
ledge of this relationship will be helpful in throwing light
on the changes seen in the present study.
A recent study by Cookson et al, (1983) showed changes in
prolactin levels in manic patients in response to intravenous
haloperidol. There was also a trend to higher than normal
levels of prolactin. This latter finding may relate to the
results of this study, although Cookson's study was conducted
under very different circumstances.
Involvement of the endorphins in modulating dopamine function
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may explain the changes in prolactin levels demonstrated by
this study. Beta-endorphin exerts an inhibitory effect on
dopaminergic inhibition (Fw:e et al, 1984). Should the
levels of endorphin be low in depression inhibition of dopa-
minergic inhibition would be reduced, i.e. dopaminergic in-
hibition would increase and prolactin levels would fall. The
converse would hold for mania producing a rise of prolactin.
Changes in mood and the experience of pain associated with
the various phases of bipolar illness may also be explained.
D-ala-enkephalin, beta-endorphin and analogues have been
shown to have opiate-like effects when administered cent-
rally. Behavioural activation occurs at low doses and anal-
gesia. High doses are associated with euphoria and sedation.
Of great interest is the fact that behavioural activation is
associated with peptide action on the mesolimbic dopaminer-
gic system (Koob et al, 1984).
This interface between the peptides and the monoamine sys-
tems requires further investigation. The reduction of
experience of pain seen clinically in mania and possibly the
increased sensitivity to pain in depression, may be associ-
ated with changes in the peptide systems. Effects on mood
are perhaps even more obvious. The present study has drawn
on this relationship quite unexpectedly.
6.1.4 Prolactin in Mania
While we can speculate on what the causes of the changes in
prolactin levels may be, the actual changes demonstrated
were borne of theoretical consideration on dopamine function
in primary affective disorders.
This study has demonstrated shifts in prolactin levels from
depressed (lower) to recovered, and from manic (higher) to
recovered, the patients having been used as their own con-
trols. The fact that no "normal" controls were used is a
drawback to this study.
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The normal values as determined for the particular assay
used are quoted as extending to 13ng/m1 (Rianen Assay Sys-
tem). A 97,5 percentile cut-off was used, having conducted
their study on 72 "normal" subjects. Frantz (1978) quotes
the upper reference as being 2Ong/m1 for males and 25ng/ml
for females in his study.
It is highly probable that a number of the manic subjects in
this study exceeded the upper limits of normal, on baseline
prolactin measures while in the manic phase. Reference to
patients identification numbers, 2, 9, 19, 26 and 27 on pages
119, 121, 127, 131 and 133 respectively, are cases in point.
These refer to five manic patients all of whom had baseline
prolactin levels beyond 13ng/ml. This holds for all five sub-
jects whether the maximum baseline values or the means of
baseline values are accepted. This would appear to be appro-
priate as the "upper normal" for this assay technique is
Quoted as 13ng/ml. Patient identification number 25 (page 117)
was virtually 80 years old when studied and as can be seen
his prolactin values are entirely out of keeping with the
other manic patients. It would appear to be legitimate to dis-
card this patients' data. Under these circumstances five of
the total of seven manic patients may have elevated levels of
prolactin. This is approximately 70% of the sample. Taking
the cut-off point as 25ng/ml three of the seven subjects'
prolactin levels extend beyond 25ng/ml, that is about 40%.
The sample is obviously small and caution must be observed in
drawing conclusions. Taken in conjunction with the previous
analyses which suggest that there are indeed statistically
significant shifts in prolactin levels from manic to recover-
ed in a downward direction, the above discussion can only be
supported. On this small sample of seven patients suggestive
evidence of elevated prolactin levels in the conservative
region of 50% of manic patients can be expected.
6.1.5 Future Development
Rating scales of a more comprehensive type should be sought.
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The narrow view reflected in the Hamilton Depressive and
Pettersen Scales are problematic. They do not adequately
allow behaviour to be viewed across the entire range of its
possibilities.
A further problem is the heavy loadings placed in areas
which do not appear to be fundamental. For instance, the
last three items of the Hamilton Scale are loaded to a max-
imum but probably all three reflect secondary cognitive
effects.
Further work needs to be done in affective disorders. Adequate
numbers of subjects to allow breakdown into bipolar and uni-
polar types will be most interesting. It is likely that the
bipolar group will show more profound disturbance of dopamine
function than will the unipolar group.
Mania is likely to be particularly rewarding despite the
operational difficulties of managing these patients. Exclusion
from the study of patients over 65 years of age appears to be
warranted in both the depressed and manic groups.
Full challenge procedures appear to be necessary as these
give considerably more information than do baseline measures
alone. The possible receptor supersensitivity revealed bears
witness to this fact.
Investigation during sleep may also prove to be productive,
following claims that disturbance of prolactin is greater in
sleeping than in waking depressive subjects (Halbreich et al,
1979).
More extensive profiles of biological data in the manic,
normal and depressed phases are certainly desirable. It is
preferable not only to study the various phases but also to
incorporate a "normal" control group of subjects. This con-
stitutes a very demanding research project, possibly a smaller
number of patients intensively investigated in the different
phases of the illness will be useful.
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It is highly desirable that biological disturbances be de-
fined in these disorders, such that organically measurable
markers be available for diagnostic, classificatory and
possibly treatment purposes.
Investigation of motor activity and prolactin level changes
from ill to recovered, or possibly manic to depressed, should
be conducted with adequate numbers of subjects. It may then
be possible to establish a causal relationship between dopa-
mine function and motor activity on the one hand, and prolac-
tin on the other. The relationship between prolactin and
motor activity thus being causally linked via dopamine.
Attention should be given to the peptide molecules and the
role of the opiate receptors. Research strategies are under
consideration in this regard.
6.2 CONCLUSION
A number of positive findings have emerged from this study.
The implications of these findings remain to be clarified. The
main findings are as follows:-
A significant change in prolactin levels from illness to
recovery phases has been demonstrated in primary affective
disorders. The depressive phase is associated with lower levels
of prolactin. This is not an absolute lowering but is relative
to the patients "well" state. Manic patients have an increase
of prolactin levels, which appear to be absolute in over 50%
of the subjects.
A number of manic subjects appear to have dopamine receptor
(D
4
) supersensitivity. A full pharmacological challenge pro-
cedure is necessary to demonstrate this effect.
The possible causes of these changes are discussed, with an
emphasis on the role of dopamine, and a brief view of possible
future studies is given. Mania remains a particularly fruitful
area for research, but it remains operationally a difficult
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condition to study.
The relationship of prolactin levels to motor activity is an
important one, in view of the probability that dopamine
regulates both motor activity and prolactin. Motor activity
may be profoundly disturbed in primary affective disorders.
Covariance of prolactin levels and ratings of motor activity
could not be demonstrated, largely as a result of sample
sizes. This defect could be corrected by extending the pres-
ent study to obtain adequate sample sizes, so that analysis
is feasible. More complex approaches or strategies may be
required to demonstrate a specific relationship between pro-
lactin and motor activity.
The present study has demonstrated a reversed pattern of pro-
lactin secretion from that which was hypothesised, indicating
a possible decrease of dopamine inhibition in mania and an
increase of inhibition in depression. Controversy still sur-
rounds the characterisation of dopamine receptors. Indica-
tions of supersensitivity of dopamine receptors in mania
suggests that disturbance of dopamine is involved in the dys-
regulation of prolactin. The changes in the receptors are
probably secondary, as this explains the data better than
primary changes in the dopamine receptors.
The responses of prolactin to challenges in the depressed
phase need to be evaluated against normal controls in order
to assess the degree of blunting of these responses.
Possible mechanism underlying the changes demonstrated are
discussed. Future studies should attempt to use the patients
as their own controls and include "normal" controls.
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